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CHAPTER 1 
PROTEIN PRENYLATION AND ITS ROLE IN HUMAN DISEASE 
  
1.1 INTRODUCTION 
 
1.1.1 Introduction to lipid modifications  
Lipid modification of proteins is an essential aspect of the expression, stability as well as 
function of the modified proteins. The most common lipids that are added to proteins 
include fatty acids (myristate, palmitate etc.) and isoprenyl groups (farnesyl and 
geranylgeranyl) (Table 1.1). Prenylation is known to modify several hundred proteins in 
cells (McTaggart, 2006). These include fungal mating factors, GTPases of the Ras 
superfamily, subunits of trimeric G proteins, nuclear proteins such as prelamin A and 
lamin B, and protein kinases (Zhang and Casey, 1996). Addition of isoprenoids is 
thought to facilitate membrane association, subcellular localization, vesicular trafficking 
and protein-protein interactions of modified substrates (Konstantinopoulos et al., 2007; 
Zhang and Casey, 1996).  
 
1.1.2 Synthesis of isoprenoids 
Isoprenoid groups are derived from the five-carbon (C5) unit isopentyl diphosphate (IPP) 
and its isomer dimethylallyl diphosphate (DMAPP). These units are synthesized via the 
mevalonate pathway of cholesterol biosynthesis (Goldstein and Brown, 1990) (Figure 
1.1). Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase is the rate-limiting 
enzyme of this pathway that catalyzes the first step of conversion of acetyl CoA to 
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mevalonate. Further, via multiple enzymatic steps, isoprenoid units are obtained. The 
farnesyl isoprenoid, farnesyl pyrophosphate (FPP) is a 15-carbon lipid group, whereas 
geranylgeranyl pyrophosphate (GGPP) is a 20-carbon moiety. Cholesterol synthesis 
also utilizes FPP, and hence a tightly regulated feedback mechanism controls the 
activity of this pathway (Brown and Goldstein, 1980). 
 
 
 
 
Table 1.1. Types of post-translational lipid modifications.  
 
1.1.3 Types of protein prenylation and prenylation targets 
Prenylation was first identified to occur in mammalian proteins when the nuclear 
envelope protein, lamin B, was found to be modified by a metabolite of mevalonic acid 
in the cholesterol biosynthesis pathway (Wolda and Glomset, 1988). This metabolite 
was later identified as a 15-carbon farnesyl group (Farnsworth et al., 1989). Alongside 
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this discovery, another modifying prenyl group was also identified, the 20-carbon 
geranylgeranyl isoprenoid group (Farnsworth et al., 1990). About the same time, other 
proteins including Ras superfamily of proteins were described as targets for 
farnesylation, and it was discovered that farnesylation is required for transformation of 
cells by oncogenic Ras (Casey et al., 1989; Hancock et al., 1989; Schafer et al., 1989). 
Sequence comparison amongst the yeast mating factor, lamin B and Ras proteins 
revealed that all these proteins contain a cysteine residue at the C-terminus, followed by 
three other residues, in most cases, -aaX [a= aliphatic amino acid, X= a variety of amino 
acids] (Farnsworth et al., 1989; Powers et al., 1986). This is termed as the CaaX box, 
which makes a component of a variety of proteins. In the Ca1a2X sequence, the 
specificity at a2 and X positions determines the specificity of CaaX sequence recognition 
by modifying enzymes. Aromatic and basic residue substitutions are tolerated at a1, but 
not at a2 (Moores et al., 1991). Aromatic residue substitution at a2 makes a substrate 
that acts as a competitive inhibitor of the prenylating enzyme (Brown et al., 1992; 
Goldstein et al., 1991).  
It is now known that there are also prenylated proteins that contain a CC or a CXC 
instead of a CAAX moiety (Glomset and Farnsworth, 1994). The C-terminal motif 
governs which isoprenoid will be attached to the protein (Figure 1.2). In case of proteins 
containing CaaX, when ‘X’ is serine, glutamine or methionine, farnesylation occurs, 
whereas when ‘X’ is a leucine, geranylgeranylation occurs (Casey et al., 1991; 
Yokoyama et al., 1991). Nonetheless, this is not an absolute rule, and cross-prenylation 
does occur. For instance, H-Ras is exclusively farnesylated, whereas K-Ras and N-Ras 
can be farnesylated or geranylgeranylated. Like Ras proteins, Rho GTPases also 
  4 
contain CaaX sequences and undergo prenylation. However, they mostly undergo 
geranylgeranylation (Konstantinopoulos et al., 2007), and after modification they bind to 
RhoGDIs (Rho guanine nucleotide dissociation inhibitors) which keep them soluble in 
the cytosol and carry them to membranes where they function (Hoffman et al., 2000). 
There is also evidence that RhoB can be farnesylated and geranylgeranylated, and the 
two modified forms exert different functions (Du et al., 1999; Lebowitz et al., 1997). 
Interestingly, geranylgeranylation is the more commonly found prenyl modification on 
cellular substrate proteins (Farnsworth et al., 1990; Rilling et al., 1990). In general, CC 
and CXC containing proteins are geranylgeranylated (Seabra et al., 1992b). These 
mainly consist of Rab family of proteins, which includes more than 60 different proteins 
(Leung et al., 2006). The steps involved in prenylation of GTPases have been depicted 
in Figure 1.3. 
 
 
 
 
Table 1.2. Comparison of properties of prenylation enzymes.  
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1.1.4 Prenylation enzymes and enzyme kinetics 
There are three distinct prenylation enzymes: farnesyltransferase (FTase), 
geranylgeranyltransferase type I (GGTase I) and geranylgeranyltransferase type II 
(GGTase II) (Moores et al., 1991; Reiss et al., 1990) (Table 1.2). The crystal structures 
of all of these enzymes are shown in Figure 1.4. Each of these is a heterodimer 
consisting of an α and a β subunit polypeptide (Moomaw and Casey, 1992; Reiss et al., 
1990; Seabra et al., 1992a). FTase and GGTase I are closely related. They share a 
common α subunit (48 kDa molecular weight) (Chen et al., 1991a; Seabra et al., 1991) 
of almost identical structures, with slight differences in their interaction with the 
corresponding β subunits (Lane and Beese, 2006). The β subunits (46 kDA in FTase; 
42 kDa in GGTase I) (Chen et al., 1991b; Moomaw and Casey, 1992; Yokoyama and 
Gelb, 1993) are distinct with ~25% sequence homology (Zhang and Casey, 1996), but 
share similar structures. Both α and β subunits are made up of α-helices and are 
arranged as a superhelical α-subunit flanking the α-α barrel β-subunit (Park et al., 1997; 
Taylor et al., 2003). This arrangement forms a deep, funnel-shaped cavity in the center 
of the barrel that is lined with several conserved aromatic residues and is hydrophobic 
in nature (Lane and Beese, 2006). The active sites of FTase and GGTase I lie within 
this cavity. The α−β interface of both enzymes is characteristic with the formation of 
several hydrogen bonds due to its highly polar nature (Janin et al., 1988).  
 FTase and GGTase I are both zinc metalloenzymes with one mole of zinc per mole of 
enzyme (Chen et al., 1993). The zinc ion is bound to the β subunit at the α−β interface 
via specific conserved residues (Lane and Beese, 2006; Park et al., 1997; Taylor et al., 
2003). Zn2+ is not essential for binding of the isoprenoid (FPP/GGPP), but is required for 
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binding of the protein substrate (Reiss et al., 1992; Yokoyama et al., 1995).  It directly 
coordinates the cysteine residue of the substrate CaaX sequence (Huang et al., 1997; 
Moomaw and Casey, 1992). Crystallographic studies as well as in vitro biochemical 
experiments suggest that the Zn2+ cofactor is critical for catalytic activity of the enzymes 
(Moomaw and Casey, 1992; Yokoyama et al., 1995). FTase also requires Mg2+ for its 
catalytic activity (Reiss et al., 1992), whereas Zn2+ alone is sufficient for full GGTase I 
activity. FTase is thought to have distinct binding sites for its two substrates, FPP and 
the peptide (Reiss et al., 1991). Both binding sites lie on the β-subunit of the enzyme 
and either substrate can bind the enzyme independently (Ying et al., 1994). However, 
steady-state kinetic analyses have shown that both substrates must bind before the 
formation of the product (Pompliano et al., 1992). This is also true for GGTase I. Like 
FTase, GGTase I has two distinct substrate binding sites on its β-subunit and substrates 
can bind the enzyme independently (Yokoyama et al., 1995). This mechanism of 
substrate binding is called the random sequential mechanism, wherein either substrate 
can bind the enzyme first. However, with both FTase and GGTase I, isoprenoid 
substrate binding first to the free enzyme is thought to be the preferred mechanism 
(Pompliano et al., 1993; Zhang et al., 1994). Nevertheless, the precise sequence of 
events in the enzymatic reaction still remains undefined.  
As mentioned earlier, the α subunits of FTase and GGTase I are almost identical. 
However, their involvement in the catalytic activity of the enzymes is not fully 
established. It has been suggested that some highly conserved residues in this subunit 
may be required for stabilizing the enzyme conformation rather than subunit interactions 
(Omer et al., 1993). There is also evidence that mutation of Lys164 to Asn of the 
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α subunit does not interfere with α−β dimerization or substrate binding, but abolishes 
the FTase enzymatic activity (Andres et al., 1993a), suggesting a direct role for the α-
subunit in FTase catalytic activity.  
Although FTase and GGTase I are generally selective for their protein substrates, their 
sequence and structural similarities lead to some degree of cross-reactivity (Zhang and 
Casey, 1996). In addition, the substrate recognition elements of their respective 
isoprenoid and protein substrates exhibit common features, attenuating substrate 
specificity. Extensive structural biological studies and sequence-based predictions have 
been made in order to understand what factors govern substrate specificity and catalytic 
mechanisms of these enzymes (Lane and Beese, 2006). Although FTase can bind both 
FPP and GGPP, it is not capable of transferring GGPP on to substrate proteins (Reiss 
et al., 1992; Yokoyama et al., 1997). In contrast, GGTase I can bind FPP and GGPP 
with comparable affinities, and is capable of transferring FPP to RhoB substrate with 
similar efficacy as GGPP (Armstrong et al., 1995; Yokoyama et al., 1995). A simple 
ruler hypothesis suggests that the two enzymes can distinguish between the lengths of 
the isoprenoid chains, which differ due to an additional isoprene unit in GGPP (Taylor et 
al., 2003). Crystal structures of the prenyltransferases in complexes with peptide 
substrates and/or isoprenoid analogs have shed light on the conformational 
requirements for enzyme-substrate interactions and product formation from these 
complexes (Lane and Beese, 2006). They indicated both substrate and prenylated 
peptide product bound simultaneously to the catalyzing enzyme and that the amino acid 
sequence of the CaaX motif may modulate product release, which was the rate-limiting 
step of the prenylation reaction. They also suggested that a small portion of the 
  8 
isoprenoid conformation moved during catalysis. The study of the prenyltransferase 
complexes also confirmed that GGTase II catalysis involves a processive reaction, 
wherein two prenyl groups are added to its Rab substrates without dissociation of a 
monoprenylated intermediate. FTase and GGTase I catalyzed reactions, on the other 
hand, are non-processive (Lane and Beese, 2006). 
The enzyme, GGTase II (also known as RabGGTase), contains both an αβ heterodimer 
that is required for catalytic action and an additional polypeptide, Rep1 (Rab escort 
protein I). GGTase II modifies proteins ending in CC or CxC that are found exclusively 
in the Rab protein family (Casey et al., 1991). In both cases, geranylgeranyl 
modification occurs at both the cysteine residues (Farnsworth et al., 1994). The α and 
β subunits of GGTase II identified from rat cDNA exhibit ~30% homology with their 
corresponding subunits in FTase and GGTase I (Armstrong et al., 1993). The GGTase 
II catalyzed reaction may, however, follow a distinct mechanism compared to the other 
prenyltransferases (Andres et al., 1993b). Purified GGTase II requires Mg2+ for its 
enzymatic activity, and is actually inhibited by the presence of Zn2+ (Seabra et al., 
1992b). Unlike in FTase and GGTase I, where the catalytic activity resides mainly in the 
β component, the αβ dimer component of GGTase II is thought to participate in its 
catalytic mechanism. Rep1 (earlier known as component A) can bind to both 
unprenylated and prenylated Rabs and thus serve mainly to escort the substrate Rab 
proteins and present them to the catalytic component heterodimer. Rep1 remains bound 
after the geranylgeranylation reaction and the reaction is limited by the amount of Rep1 
protein, which keeps the Rabs soluble in the cytosol. Finally, prenylated Rabs bind 
RabGDIs (Rab guanine nucleotide dissociation inhibitors), which recognize the double 
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geranylgeranyl moieties and help translocate them to the plasma membrane where they 
can function (Andres et al., 1993b).  
 
1.2 ADDITIONAL POST-TRANSLATIONAL MODIFICATIONS 
 
1.2.1 Two-signal hypothesis 
Most proteins that are subject to prenylation, including GTPase proteins, are required to 
be membrane-bound in order to function effectively. Prenyl groups, being hydrophobic 
in nature, are capable of assisting their substrate proteins to translocate toward their 
target membrane, wherein they can bind to membrane lipids and to other proteins and 
thereby efficiently participate in signaling pathways. The increase in hydrophobicity, 
however, may not be sufficient for the prenylated protein to remain membrane-bound for 
the required duration, especially in case of a singly farnesylated protein (Peitzsch, 1993; 
Silvius and l'Heureux, 1994). This observation led to the two-signal hypothesis, 
suggesting the requirement of a second signal, either a palmitate or a polybasic domain 
immediately upstream of the prenylated cysteine (Resh, 2006). Either one of these 
signals significantly enhances membrane affinity of an already prenylated protein and 
helps stabilize it in the lipid bilayer (Dunphy and Linder, 1998; Hancock et al., 1990). For 
instance, K-Ras4B, which contains a polybasic domain close to the C-terminus 
demonstrates enhanced membrane association when compared with its mutant lacking 
the basic residues in this region (Hancock et al., 1990). Similarly, H-Ras contains two 
palmitoylation sites, Cys181 and Cys184. When these residues are mutated to Ser, the 
percentage of membrane associated H-Ras is drastically diminished (Hancock et al., 
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1989). Since geranylgeranylation via GGTase II already attaches two lipid moieties to 
the protein that results in improved hydrophobicity, it leads to quite effective membrane 
association (Shahinian and Silvius, 1995). Moreover, CXC-containing proteins further 
undergo methylation, whereas CC-containing proteins do not undergo further 
modifications (Farnsworth et al., 1991; Smeland et al., 1994). In contrast, a farnesylated 
protein exhibits modest membrane association that is only short-lived, and thus requires 
additional signals to stabilize its interaction with membranes.   
 
1.2.2 Post-prenylation processing 
Following prenylation, many proteins undergo further modifications via other modifying 
enzymes. These additional processes can occur at different locations inside the cell 
along the proteins’ secretory pathway. The first step after prenylation at the cysteine 
residue involves cleavage of the –aaX residues by an endoprotease. This was first 
found to occur in yeast and mammalian Ras proteins and confirmed in vitro (Fujiyama et 
al., 1987; Gutierrez et al., 1989; Ma and Rando, 1992). The enzyme responsible is 
known as Ras converting enzyme 1 (RCE1) and is present at the endoplasmic reticulum 
(ER) membrane (Boyartchuk et al., 1997; Schmidt et al., 1998).  
The next step is methylation at the exposed carboxyl group of the prenylated cysteine, 
which also occurs at the ER (Stephenson and Clarke, 1992). All CaaX containing 
proteins and some Rab proteins containing CXC but not CC are methylated (Clarke, 
1992; Farnsworth et al., 1994). An isocarboxyl methyltransferase (ICMT) enzyme 
activity present in ER fraction of cells is responsible for modification of CaaX substrates. 
Some of this enzyme may also be present in plasma membranes (Pillinger et al., 1994) 
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and its activity is thought to be stimulated by the γ−subunit of G-protein (Backlund et al., 
1990). ICMT utilizes S-adenosyl-L-methionine as a methyl donor (Perez-Sala et al., 
1992; Pillinger et al., 1994). Substrate recognition is highly dependent on the isoprenoid 
attached to the cysteine. Both farnesyl and geranylgeranyl substrates are recognized 
equally well (Tan et al., 1991). The kinetics of this enzymatic step have been studied 
(Shi and Rando, 1992). A distinct methyltransferase is required for modification of CXC-
type proteins (Giner and Rando, 1994) which has not been explored in detail. 
Methylated proteins are further subjected to palmitoylation, when necessary, at the 
Golgi, which then facilitates their translocation toward plasma membranes 
(Konstantinopoulos et al., 2007). A family of several palmitoyl acyltransferases (PATs) 
can carry out this step (Feng and Davis, 2000; Mitchell et al., 2006).  
 
1.2.3 Reversibility of prenylation 
Many post-translational modifications are known to be reversible. Palmitoylation is a 
dynamic lipid modification due to its reversibility. Palmitoylated proteins localize in 
plasma membranes, including lipid rafts (Moffett et al., 2000). After it has performed its 
function, depalmitoylation by thioesterase enzyme helps release of the protein from the 
membrane and transfer back to the Golgi where it can get repalmitoylated (Rocks et al., 
2005). The balance between PAT and palmitoyl thioesterase activities determines the 
relative abundance of palmitoylated versus non-palmitoylated protein levels 
(Baekkeskov and Kanaani, 2009). In contrast, prenylation is thought to be a stable, 
irreversible modification. Theoretically, it has been suggested that reversible prenyl 
group attachment could be part of a ‘prenyl switch’ to facilitate their release from the 
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lipid bilayer (Resh, 2006), regulating the prenylation process. This hypothesis, however, 
lacks experimental evidence. 
 
1.3 SIGNIFICANCE OF PROTEIN PRENYLATION 
 
1.3.1 Membrane targeting 
As mentioned previously, the most important function of prenylation is to alter the 
hydrophobicity of the substrate protein and facilitate localization to the plasma 
membrane or other membranes, where it can associate with the membrane 
components and serve its functions. The efficiency of membrane targeting varies with 
the type of prenyl group attached, and the second signal functions to augment the 
efficiency when it is low. For instance, post-prenylation processing is required for proper 
localization of all Ras isoforms, but not necessary for Rho targeting (Michaelson et al., 
2005).  
 
1.3.2 Subcellular localization  
The highly variable C-terminal domain of a prenylated protein determines its specific 
membrane localization (Chavrier et al., 1991). For example, lamin B contains a nuclear 
localization signal that targets it to the nucleus (Holtz et al., 1989). Similarly, the C-
terminal polybasic region of K-Ras4B serves as a trafficking signal to direct it to plasma 
membranes (Hancock et al., 1990) but not to lipid rafts. This region may also direct 
subsequent translocation of K-Ras4B from the plasma membrane to the Golgi and 
endosomal membranes (Fivaz and Meyer, 2005). In comparison, H-Ras and N-Ras, 
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which do not contain such a polybasic domain, are targeted via the exocytic pathway to 
plasma membranes, and reside both inside and outside of lipid rafts (Apolloni et al., 
2000). Both these isoforms are also present in endomembrane systems including 
endosomes, ER and the Golgi (Choy et al., 1999). The Ras proteins associated with 
any of these cellular locations are capable of being activated for GTP hydrolysis, 
although via distinct mechanisms (Bivona et al., 2003; Chiu et al., 2002; Rotblat et al., 
2004).  
 
1.3.3 Protein-protein interactions 
Not only do GTPases interact with cellular membranes, but they also interact with other 
proteins. It is likely that their membrane association also involves protein-protein 
interactions. They can bind to components of lipid rafts for stable membrane binding 
(Simons and Toomre, 2000). Inactive H-Ras is partially localized to lipid rafts and when 
activated it relocates laterally to the non-raft regions of the plasma membrane for signal 
transduction (Prior et al., 2001). GTPases are required to cycle between membranes 
and cytosol, which calls for a reversible association. This is achieved by means of 
binding to specific proteins called guanine nucleotide dissociation inhibitors (GDIs) and 
guanine nucleotide exchange factors (GEFs) (Orita et al., 1993; Pfeffer et al., 1995; 
Steele-Mortimer et al., 1993). GEFs, such as SOS, facilitate exchange of GTP for GDP 
from the active proteins such as K-Ras situated at the plasma membrane, allowing their 
dissociation from the membrane. Similarly, binding of prenylated Rho to RhoGDI 
protects the isoprenoid group from the environment in the cytosol as well as facilitates 
dissociation from the membranes (DerMardirossian and Bokoch, 2005). GDIs are 
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capable of binding prenylated but not unprenylated Rab and Rho proteins, thus 
maintaining them in the cytosol in a GTP-dependent manner (Olofsson, 1999; Pfeffer et 
al., 1995). GTP binding causes dissociation of GDI to allow membrane translocation, 
and after GTP hydrolysis to GDP, GDI can bring the protein back into the cytosol 
(DerMardirossian and Bokoch, 2005).  
Prenylation also contributes to formation of multisubunit complexes, e.g. the βγ complex 
of trimeric G proteins. Unprenylated γ subunit is more efficient in dimerizing with β than 
is the prenylated γ species. However, prenylation of γ subunit is required for the 
interaction of βγ with the α subunit (Higgins and Casey, 1994). Furthermore, the 
interaction of these complexes with a receptor is influenced by the type of prenyl group 
present on the γ subunit (Kisselev et al., 1995).  
 
1.3.4 Protein function 
As mentioned above, prenylation is necessary for maintenance of many different 
phenomena related to a protein, which ultimately determine its functional efficiency. 
Therefore, regulation and modification of prenylation properties of proteins emerged as 
a critical way of manipulating their functions in the cell. Since Ras is the most commonly 
mutated oncoprotein in different types of cancer, and particularly because oncogenic 
forms of Ras require farnesylation to be able to transform cells, it was thought that 
targeting farnesylation would be of potential use to control Ras function and achieve 
anti-tumor action (Konstantinopoulos et al., 2007). Designing compounds targeted to 
inhibit prenylation enzymes tested this hypothesis. Several classes of such inhibitors 
have been designed and tested pre-clinically as well as clinically (Sebti and Hamilton, 
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2000). Some of these have shown promising results and have been further developed 
for use in vitro and in vivo for various therapeutic applications (Gelb et al., 2006). More 
recently, other inhibitors of the posttranslational processing of prenylated proteins have 
also been tested singly or in combination with each other or with traditional anticancer 
therapies in order to achieve improved inhibition of prenylation (Lobell et al., 2001; 
Wojtkowiak et al., 2009). Among these inhibitors are statins, bisphophonates and ICMT 
inhibitors (Figure 1.5).  
 
1.4 PRENYLATION INHIBITORS 
 
1.4.1 Statins 
Statins are the most widely prescribed drugs for hypercholesterolemia associated with 
coronary artery disease. They inhibit the rate-limiting enzyme HMG-CoA reductase of 
the mevalonate pathway, which catalyzes the initial step in the formation of mevalonate 
for biosynthesis of cholesterol. Statins not only inhibit the synthesis of cholesterol, but 
also interfere with the formation of the intermediate isoprenoids, FPP and GGPP, that 
are required for prenylation. Due to this action, statins have been used for anticancer 
effects in a number of different types of cancer (Sassano and Platanias, 2008). Apart 
from the above-mentioned effects, they are also useful as immunomodulators. They 
have been shown to bind to the integrin, leukocyte function antigen 1 (LFA1) and 
reduce invasion and migration of pro-inflammatory leukocytes, although in low 
micromolar concentrations (Weitz-Schmidt et al., 2001). Extrapolating this observation, 
they have been explored for use in several autoimmune disease models, e.g. 
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experimental autoimmune encephalitis (EAE) model for multiple sclerosis (Weber and 
Zamvil, 2008).  
Lovastatin was the first to be identified among statins and it is a naturally occurring 
compound. The main mechanism of action of lovastatin and its other family members 
including simvastatin is believed to be inhibition of RhoA and Rac1 geranylgeranylation 
(Nakagami et al., 2003; Zhong et al., 2003). Lovastatin was also recently found to inhibit 
Ras farnesylation and induce apoptosis in K-Ras transformed thyroid cells (Laezza et 
al., 2008). Many statins have been shown to exert their effect on cell cycle progression 
by altering p21 and/or p27Kip1 levels, leading to G1 cell cycle arrest in a p53-
dependent or -independent manner (Naderi et al., 1999; Saito et al., 2008). Statins exert 
pleiotropic effects on cancers, some of which may be undesirable (Gonyeau and Yuen). 
They can aid antitumor therapy via inhibition of cancer cell growth and/or angiogenesis 
or via induction of apoptosis. 
Statins are well-tolerated in patients, although cancer monotherapy with statins in 
clinical trials exhibited dose-limiting toxicities including hepatotoxicity, nephrotoxicity, 
gastrointestinal toxicity, myelotoxicity and rhabdomyolysis (Konstantinopoulos et al., 
2007). Cerivastatin was withdrawn from the market in 2001 due to high incidence of 
rhabdomyolytic toxicity in patients. Several statins (eg. fluvastatin, simvastatin) are 
being evaluated currently as chemopreventive agents in clinical trials for cancers 
including breast, colorectal, non-small cell lung cancer (NSCLC) and so on (Sleijfer et 
al., 2005). Lovastatin trials are being set up for testing its safety and efficacy in 
neurofibromatosis type 1 (NF1) patients. In most ongoing clinical trials, statins are being 
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used as adjuvants with other chemotherapeutics, or for chemoprevention in cases of 
recurrence after chemotherapy, surgery and radiation therapy (www.clinicaltrials.gov).  
 
1.4.2 Bisphosphonates 
Bisphosphonates (BPs) are compounds that inhibit two different enzymes in the 
mevalonate pathway, isopentenyl diphosphate (IPP) isomerase and FPP synthase. 
Both these enzymes catalyze steps upstream of FPP and GGPP synthesis (Figure 1.1) 
and hence carry potential to inhibit all routes of protein prenylation. BPs are divided into 
two different classes of compounds. It is the nitrogen-containing 
(aminobisphosphonates) class (N-BPs) that inhibits prenylation, unlike the class of 
compounds lacking nitrogen, which have a different mode of action (Rogers et al., 
2000). In addition, the N-BPs are more potent.  
N-BPs (zoledronic acid, pamidronate, ibandronate etc.) are  used primarily for the 
prevention and treatment of osteoporosis and are also indicated for bone-related 
complications associated with bone metastases arising from several neoplasms 
including breast cancer (Caraglia et al., 2006). These drugs directly inhibit the activity of 
osteoclasts, the cells that are responsible for bone resorption, owing to their high affinity 
for calcium (Papapoulos, 2008). Their uptake by osteoclasts occurs via bone resorption 
facilitated by the P-C-P backbone of their chemical structure. There is in vitro and in 
several cases in vivo evidence that the mechanisms of action of N-BPs include G1 and 
S-phase cell cycle arrest and induction of apoptosis in osteoclasts, inhibition of tumor 
cell adhesion and invasion into the extracellular matrix as well as inhibition of 
angiogenesis (Green, 2003). It has been suggested that the main actions of N-BPs on 
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osteolysis may be due to blockade of geranylgeranylation of Rho and Rab family 
proteins (Coxon et al., 2005; Fisher et al., 1999). Most recently, a class of lipophilic BPs 
has emerged as a group of potential anticancer agents with enhanced activity and 
improved potency attributed to increased lipophilicity and hence attenuated affinity for 
the bone (Zhang et al., 2009).   
Zoledronic acid is the most studied BP and like several other BPs of its class, it was 
thought to be promising for use in prevention of bone loss in breast cancer and prostate 
cancer (Doggrell, 2009; Lyseng-Williamson, 2008). It was also thought that these 
bisphosphonates could be beneficial in treatment of metastatic bone disease associated 
with breast, prostate, lung cancers as well as multiple myeloma. Initial clinical trials 
found that zoledronic acid, ibandronate and pamidronate may be useful in improving the 
outcome of such patients, whereas clodronate did not show significant effects of 
prolonged survival and also exhibited some toxicity (Bauss and Bergstrom, 2008; Body 
and Mancini, 2002; Gnant, 2009). Several clinical trials are currently being undertaken 
to evaluate the performance of BPs particularly as adjuvants with chemotherapy or 
radiation therapy (Bauss and Bergstrom, 2008) (www.clinicaltrials.gov). 
 
1.4.3 Icmt and Rce1 inhibitors 
Isocarboxymethyl transferase (Icmt) and Ras converting enzyme 1 (Rce1) inhibitors 
prevent post-prenylation modification of proteins via carboxymethylation. Effects of 
disruption of Icmt and Rce1 genes have been studied in vitro and in vivo. Complete 
ablation of the Icmt gene in mice is embryonically lethal (Bergo et al., 2004), whereas 
Rce1 genetic ablation was much more tolerable (Bergo et al., 2002). Inhibition of Icmt 
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activity resulted in impaired transforming capability of oncogenic Ras (Wahlstrom et al., 
2008). In contrast, inhibition of Rce1 activity worsened the myeloproliferative disease 
caused by oncogenic K-Ras (Wahlstrom et al., 2007). Both peptide and non-peptide 
Rce1 inhibitors have been developed (Schlitzer et al., 2001; Winter-Vann and Casey, 
2005). Icmt inhibitors were first made as S-adenosylhomocysteine (AdoHcy) analogs, 
which exhibited anti-tumor activity (Wnuk et al., 1997).  Subsequently, analogs of the 
substrate N-acetyl-S-farnesylcysteine were synthesized and evaluated, but were found 
to be weak inhibitors (Henriksen et al., 2005). Indole-based small molecule inhibitors 
followed these and also showed anti-tumor activity in human colon cancer cells (Winter-
Vann et al., 2005). One such compound, cysmethynil, when used in the MDA-MB-231 
breast cancer cells, impairs cell adhesion and cell spreading via inhibition of RhoA and 
Rac1 activity (Cushman and Casey, 2009). Spermatinamine, a natural Icmt inhibitor, 
was also discovered and can potentially be a useful inhibitor in the future (Buchanan et 
al., 2007).  
Despite these efforts, this class of inhibitors has not moved into the clinic due to 
anticipated issues. These include the concern that Icmt and Rce1 modify many more 
target proteins than FTase or GGTase, thus their inhibition may concur higher toxicity. 
The toxicity observed that is of highest concern is atherosclerotic vascular injury 
associated with endothelial cell apoptosis (Kramer et al., 2003).  
 
1.4.4 Prenyl transferase inhibitors (PTIs) 
This class consists of farnesyl transferase inhibitors (FTIs) and geranylgeranyl 
transferase inhibitors (GGTIs). They target the enzymatic activity of FTase or GGTases 
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to achieve desired effects. Several strategies have been developed over the years to 
synthesize drugs for this purpose. Our existing knowledge of enzyme kinetics as 
discussed earlier has served as an invaluable tool in the design of various competitive 
inhibitors including peptidomimetics (CaaX peptide analogs), small molecule inhibitors, 
and isoprenoid substrate analogs (FPP or GGPP analogs). Many of these have been 
studied for their potential benefits in various types of cell and animal models of cancer 
and further evaluated in human clinical trials as well (Sebti and Hamilton, 2000).  
FTIs were initially designed with the intention of targeting Ras farnesylation, since it was 
known that oncogenic Ras is involved in over 30% of all human cancers. CaaX peptide 
inhibitors of FTase were the first ones in this category. This approach was initially 
hindered by the fact that the peptides were not taken up by the cells efficiently and 
underwent rapid degradation (Zhang et al., 1994). However, CaaX tetrapeptide 
derivatives that were more effective also evolved (Stradley et al., 1993). Treatment of 
transgenic H-Ras, but not K-Ras and N-Ras, mouse models with the CaaX mimetic, L-
744832, resulted in drastic regression of salivary and mammary carcinomas (Kohl et al., 
1995). Further, high throughput screening methods followed by structural optimization 
techniques allowed identification of small molecule inhibitors of FTase. These 
compounds, e.g. lonafarnib and tipifarnib, exhibited potent activity in vitro and emerged 
as promising potential anticancer agents in preclinical studies with negligible toxicity 
[reviewed by (Basso et al., 2006)]. In several clinical trials, however, when used as 
monotherapy, FTIs failed to show significant benefits and also caused considerable 
toxicity, particularly nephrotoxicity (Konstantinopoulos et al., 2007). It was later thought 
that the cause for this unexpected toxicity may be that there are numerous farnesylated 
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proteins in the cell that may be affected by FTase inhibition. Other Ras family proteins, 
such as Rho, Rheb proteins and nuclear lamins surfaced as potential targets of FTIs in 
their FTase inhibitory action (Basso et al., 2006). Many of these other Ras proteins were 
also identified to be aberrantly regulated in certain tumors. For instance, Rheb is 
upregulated in transformed cells and human tumor cells (Jiang and Vogt, 2008; Lu et 
al.), while two different isoforms of Rho, i.e. RhoA and RhoB, are differentially involved 
in tumor cell invasion, adhesion and survival (Karlsson et al., 2009). These proteins 
may, therefore, be important FTI targets and may play key roles in their anti-tumor 
effect.  
The mechanisms of action of the current classes of known FTIs encompass multiple 
different pathways including interference with cell cycle progression via G1 phase arrest, 
induction of apoptosis and cell death, and most recently, induction of autophagic 
pathway (Pan et al., 2008; Qiu et al., 2007; Tamanoi et al., 2001). In addition, 
researchers observed that upon treatment with FTI, some proteins including K-Ras and 
N-Ras can undergo alternative geranylgeranylation via GGTase enzymes (Lerner et al., 
1997). On the other hand, more extensive screening of possible FTI targets also 
revealed that the geranylgeranylation of certain Rab proteins can be blocked by FTIs 
(Lackner et al., 2005). These studies suggested that the inhibition of several prenylated 
proteins (such as Ras, Rho, Rab etc.) may contribute to the effects exerted by FTIs on 
cells. It also eluded to the possibility of a major role for geranylgeranylation of proteins 
in their signaling mechanisms. This thought has led to a rise in the search for effective 
GGTI compounds.  
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Similar to FTIs, various classes of GGTIs have been developed and tested pre-
clinically, including peptide mimetics, small molecules and GGPP analogs. Since a 
much higher number of proteins in the cell undergo geranylgeranylation compared to 
farnesylation, GGTIs were initially expected to be less selective, and hence more toxic 
to cells. However, a small molecule inhibitor, GGTI-298, was shown to inhibit cell cycle 
progression via G1 phase arrest in a wide variety of cancer cell lines such as A549 lung 
adenocarcinoma cells (Miquel et al., 1997). This inhibition was accompanied by p53-
independent induction of the cyclin-dependent kinase inhibitor, p21 (Vogt et al., 1997). It 
was also suggested that the geranylgeranylated protein, RhoA, might be the target of 
inhibition by GGTI-298 (Adnane et al., 1998). In addition, based on the literature, current 
GGTIs show promise as effective antitumor agents in leukemic, pancreatic and breast 
cancer cell lines, as well as in breast tumor xenograft models, with reasonable toxicity 
(Kazi et al., 2009; Watanabe et al., 2008). Despite great efforts with GGTI compounds, 
their dose-limiting toxicities seem to decelerate their advancement through later phases 
of drug development. In an attempt to reduce toxicities associated with FTIs and GGTIs, 
Lobell et al used combinations of both these drugs in cancer cell lines and in tumor 
xenografts. They showed that the dual prenylation inhibitors (DPIs) or a combination of 
an FTI and a GGTI was capable of inhibiting K-Ras prenylation, however, continuous 
infusion of GGTI alone or in combination with FTI was lethal to mice (Lobell et al., 
2001). These data suggest that the FTI-GGTI combination treatment regimen should 
not be pursued. Nevertheless, combination of different inhibitors with conventional 
chemotherapeutics or radiation therapy is considered to be the most promising regimen 
(Sebti and Hamilton, 2000). The Sebti group has attempted to substantiate this idea. 
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They have shown that GGTI-2154 when combined with cisplatin, gemcitabine or taxol is 
more efficacious than monotherapy (Sun et al., 1999). Even so, additional extensive 
testing is required to discover better combination regimens that will prove to be 
successful in future clinical trials.  
 
 
 
 
Table 1.3. Potential therapeutic implications of post-translational modification inhibitors.  
 
1.5 PRENYLATION INHIBITION AND HUMAN DISEASE 
 
1.5.1 FTIs as parasitic disease therapeutics 
FTIs have been shown to be useful in the treatment of parasitic diseases. Trypanosoma 
brucei that causes African sleeping sickness and the malaria-causing parasite 
Plasmodium falciparum are both susceptible to FTI treatment (Eastman et al., 2006). 
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Growth of these protozoa is severely impaired under the influence of FTI as antiparasitic 
agents, (Wiesner et al., 2004; Yokoyama et al., 1998). One of the reasons for this 
activity of FTIs is thought to be abolishment of host enzyme activity, since these 
protozoa lack GGTase I but express FTase. Several existing FTI compounds have been 
tested for their antiprotozoal activity and the tetrahydroquinoline containing FTIs 
synthesized by Bristol-Myers Squibb demonstrated the most potent activity (Eastman et 
al., 2006). This application has broadened the range of usefulness of FTIs and may 
further assist in the development of improved FTI drug moieties.  
 
1.5.2 Prenylation in progeria 
Hutchinson-Gilford progeria syndrome (HGPS) is a rare premature aging disease 
characterized by growth retardation, hair loss, accelerated aging and early mortality that 
occurs due to atherosclerotic complications in most cases. Highly misshapen, blebbed 
fibroblastic nuclei are pathological hallmarks of this condition (Goldman et al., 2004). 
HGPS is commonly caused by a de novo mutation in a nuclear protein called lamin A 
(LMNA), resulting in an aberrantly spliced 50 amino acid-deleted form of LMNA (or 
progerin). This deletion encompasses a zinc metalloproteolytic site called Zmpste24 
that facilitates CaaX processing. Thus, progerin cannot undergo endoproteolytic 
cleavage and remains constitutively farnesylated (Glynn and Glover, 2005). In recent 
years, FTIs have been shown to block and possibly reverse the nuclear morphology 
defects in fibroblasts derived from HGPS patients and improved the progeroid 
phenotype in HGPS mouse models (Fong et al., 2006; Gelb et al., 2006). Clinical trials 
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are being set up to develop the FTI, lonafarnib, as a progeria drug 
(www.clinicaltrials.gov).  
 
1.5.3 Prenylation inhibitors and cancer 
As discussed earlier, FTIs and GGTIs have been very promising in numerous cancer 
cell models. They may serve as better anticancer drugs, however, in combination with 
other therapies (Konstantinopoulos et al., 2007). Our group and others have shown that 
prenyl transferase inhibitors and statins or bisphosphonates act synergistically to exert 
cytostatic and/or cytotoxic effects on different types of tumor cells (Andela et al., 2002; 
Morgan et al., 2005; Wojtkowiak et al., 2008).  
The primary goal of our laboratory is to target GTPases of the Ras superfamily of 
proteins, many of which are known to be aberrantly regulated in several types of human 
tumors. We achieve this by pharmacological intervention in the form of agents that 
inhibit prenylation of these proteins. Thus, we have been actively evaluating novel 
prenylation inhibitors, synthesized as isoprenoid analogs, for their potential antitumor 
activity. We combine these compounds with low doses of the HMG-CoA reductase 
inhibitor, lovastatin, in an attempt to potentiate their activity while minimizing side-effects 
(Wojtkowiak et al, 2009). The rationale underlying our approach is that the statin would 
inhibit early steps in the isoprenoid synthesis pathway and reduce the endogenous 
FPP/GGPP pools, such that the FPP/GGPP analog-based inhibitor could better 
compete out the remaining pyrophosphate (Wojtkowiak et al., 2009). Malignant 
peripheral nerve sheath tumors (MPNSTs) have served as a very useful model to 
conduct these studies. We study three distinct MPNST cell lines. Of these, NF90-8 and 
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ST88-14 were derived from neurofibromatosis type 1 (NF1) patients who carry a 
mutation in the neurofibromin (Nf) gene. This mutation leads to constitutive Ras 
activation in the cells and results in schwannomas (now called MPNSTs). Therefore, 
blocking Ras prenylation may inhibit Ras function, which may further prohibit Ras-
induced proliferation of these malignant cells. We have previously shown that a novel 
FTase inhibitor, FTI-1, when combined with lovastatin induces apoptosis in the NF1 
MPNST cell lines, NF90-8 and ST88-14 (Wojtkowiak et al., 2008). More recently, some 
groups have shown that other post-translational modification inhibitors induce 
autophagy, which may result in non-apoptotic cell death (type II cell death) (Araki and 
Motojima, 2008; Pan et al., 2008; Wang et al., 2008b). 
We have now evaluated a novel GGPP analog-based GGTase inhibitor, GGTI-2Z, in 
the STS-26T MPNST cell line. STS-26T cells were derived from a patient with a 
sporadic case of MPNST, who had no known mutations in the Nf gene. All three 
MPNST cell lines mentioned above express detectable levels of predominantly N-Ras 
and some K-Ras, while they lack H-Ras expression (Mattingly et al., 2006). 
 
1.6 SPECIFIC AIMS 
 
Aim 1: Characterize a novel GGPP analog-based geranylgeranyl transferase 
inhibitor, GGTI-2Z, and study the effect of its combination with potent doses of 
lovastatin on STS-26T MPNST cell line. 
Our collaborator’s group had recently synthesized a novel class of GGPP analogs 
based on the structure of GGPP. These consisted of analogs with different substitutions 
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at positions 3- and 7- with either allyl or vinyl groups (Maynor et al., 2008). Of all these 
substitutions, 7-allyl yielded the most potent inhibitor of GGTase I enzyme in vitro with a 
Km value of ~27nM without any significant binding to FTase. My working hypothesis for 
this aim is that GGTI-2Z, the novel compound derived from 7-allyl GGPP, in 
combination with low doses of lovastatin may potentially be effective as an antitumor 
agent in a culture model of STS-26T MPNST cells. Its mechanism of action may be 
similar to or distinct from that of the related inhibitor, FTI-1, as tested previously in our 
laboratory. 
 
Aim 2: Delineate the mechanism of induction of an aborted autophagic program 
by FTI-1/lovastatin combination in STS-26T MPNST cell line. 
As mentioned above, FTI-1/lovastatin therapy induced apoptosis in NF1 MPNST cell 
lines, NF90-8 and ST88-14. When Wojtkowiak J.W. in the laboratory tested this 
combination in STS-26T cells, he observed a mechanistically distinct effect on these 
cells. He observed that there was no induction of apoptosis in these cells, however, 
there was a robust induction of the autophagic pathway. Moreover, this autophagy did 
not undergo completion and resulted in a non-apoptotic cell death (type II cell death) 
along with procathepsin trafficking defects. My working hypothesis for this aim is that 
besides induction of autophagy, the compounds may exert a distinct effect on the 
cellular proteolytic machinery that serves as the underlying mechanism of this aborted 
autophagic program and non-conventional cell death.  
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Figure 1.1. The mevalonate pathway of cholesterol biosynthesis. Acetyl-CoA is first 
converted to mevalonate via the rate-limiting enzyme, HMG-CoA reductase. Isopentyl-
PP (IPP) is obtained, which is further modified to farnesyl pyrophosphate (FPP). IPP 
isomerase and FPP synthase enzymes catalyze intermediate steps in this pathway. 
FPP can be utilized by farnesyl transferase (FTase) to modify proteins or can be 
converted to geranylgeranyl pyrophosphate (GGPP). GGPP prenylates substrate 
proteins via geranylgeranyl transferase (GGTase). Finally, FPP may also alternatively 
be converted to cholesterol, which provides a positive feedback to regulate the rate-
limiting step of the pathway.  
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Adapted from Philips and Cox, J. Clin. Inv., 2007 
 
Figure 1.2. General schematic of prenylation pathways. G-proteins of the Ras family 
containing C-terminal CaaX moieties (where X=methionine, M or serine, S) are 
farnesylated via FTase and undergo additional modifications by other enzymes and 
translocate to the plasma membrane. Some proteins, such as K-Ras and N-Ras (where 
X=leucine, L) or other proteins containing CC or CXC at the C-terminus are 
geranylgeranylated via GGTase I or GGTase II followed by additional modifications and 
membrane translocation. 
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Figure 1.3. Prenylation reactions of GTPases. A. H-Ras, N-Ras and K-Ras are 
prenylated (H-Ras is only farnesylated, whereas N-Ras and K-Ras can be farnesylated 
or geranylgeranylated) followed by proteolytic removal of the AAX tripeptide by RAS 
converting enzyme 1 (RCE1) and carboxymethylation by isoprenylcysteine 
carboxymethyltransferase (ICMT) in the endoplasmic reticulum. Subsequently, they 
undergo palmitoylation in the Golgi and translocate to the plasma membrane to which 
they attach through their farnesyl (F) or geranylgeranyl (GG), and palmitoyl moieties (P).  
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Figure 1.3 contd. B. Rho GTPases are prenylated followed by proteolytic removal of 
the AAX tripeptide by RCE1 and carboxymethylation by ICMT. Subsequently, they bind 
to RhoGDIs, which deliver them to various membrane locations where they function. C. 
Most Rab GTPases contain C-terminal C-X-C or C-C residues (where C=cysteine and 
X=another amino acid). They are doubly geranylgeranylated as shown by GGTase II. 
Unprenylated Rab GTPases are presented by REP1 (RAB escort protein 1) to GGTase 
II. Subsequently only Rabs ending in C-X-C undergo carboxymethylation by ICMT. They 
attach to various membranes through their two GG moieties. 
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Figure 1.4.  Three-dimensional structures of prenyltransferase enzymes. Overall 
structures of A. FTase, and B. GGTase-I, with the α subunit shown in red, the β subunit 
in blue and yellow, respectively, and the catalytic zinc ion in magenta. C. Superposition 
of FTase (blue) and GGTase-I (yellow) demonstrates the structural homology of the β 
subunit of these enzymes. 
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Figure 1.4 contd. D. Overall structure of GGTase II with the α subunit shown in pink, 
the β subunit in blue, and the catalytic zinc ion in brown. 
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Figure 1.5. Classes of post-translational modification inhibitors. The mevalonate 
pathway has been targeted by several different classes of inhibitors. Statins inhibit 
HMG-CoA reductase and, therefore, are capable of inhibiting both the cholesterol 
synthesis and protein prenylation arms of the pathway. Bisphosphonates (BPH) inhibit 
IPP and FPP synthase. FTase inhibitors (FTIs) block FTase, while GGTase inhibitors 
(GGTIs) inhibit GGTase I and/or II. There are other post-translational modification 
inhibitors including Icmt inhibitors and RCE1 inhibitors.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 MATERIALS 
2.1.1 Synthetic Chemistry 
The synthetic chemistry to produce novel compounds used in these studies was 
performed in the Gibbs laboratory at Purdue University. Prodrug GGTI-2Z is a derivative 
of 7-allyl GGPP (referred to as compound 2 in Figure 2.1), which was the most potent of 
all the GGPP analogs tested in previous in vitro studies. Synthesis of 7-allyl GGPP was 
described previously (Maynor et al., 2008). 2-Z-geranylgeraniol (2-Z-GGOH) was 
synthesized from 7-allyl GGPP via a multi-step chemical reaction. It was then converted 
by phosphoramidation to prodrug GGTI-2Z. The schematic synthesis is described in 
Figure 2.1. 
 
2.1.2 Reagents 
GGTI-2Z and FTI-1 (previously described in (Clark et al., 2007)) aliquots were prepared 
in dimethyl sulfoxide (DMSO) and stored at -80oC. HA14-1 (Ryan Scientific Inc., Isle of 
Palms, SC) and lovastatin (Sigma-Aldrich, St. Louis, MO) aliquots were prepared and 
stored similarly. Bafilomycin A1 (Calbiochem, Gibbstown, NJ), 3-methyladenine and 
wortmannin (Sigma-Aldrich, St. Louis, MO) aliquots were stored at -20oC. A plasmid 
(pRK7.GFP.H-Ras.CaaX) encoding green fluorescent protein (GFP) fused to the C-
terminal 10 amino acids of rat H-Ras sequence, which encompasses its CaaX 
sequence, was constructed by subcloning into the pRK7.GFP plasmid (Yang and 
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Mattingly, 2006), a forward primer with the sequence 
5’GATCCGGCTGCATGAGCTGCAAATGTGTGCTGTCCTG3’ and a reverse primer 
with the sequence 5’AATTCAGGACAGCACACATTTGCAGCTCATGCAGCCG3’ using 
the sticky-end ligation method. 
 
2.2 METHODS 
2.2.1 Cell Culture  
STS-26T cells and normal, spontaneously immortalized rat Schwann cells (iSC) were 
obtained and maintained as described previously (Wojtkowiak et al., 2008). HEK293 
cells were cultured and transfected as previously described (Norum et al., 2005). The 
murine hepatoma 1c1c7 cell line was obtained from Dr. J. Whitlock, Jr. (Stanford 
University, Palo Alto, CA) and cultured in minimal essential medium containing 5% fetal 
bovine serum with 100 units/ml penicillin and 100 mg/ml streptomycin. Derivatives of 
1c1c7 cells that stably expressed GFP-LC3 were generated by transfection of an 
expression plasmid obtained from N. Mizushima (Tokyo Medical and Dental University, 
Tokyo, Japan). The MCF7 and MCF10.DCIS cell lines were obtained from the Cell 
Lines Resource (Karmanos Center Institute, Detroit, MI). MCF10.DCIS cells were 
maintained as a monolayer in DMEM/F12 containing 5% horse serum, 20 ng/ml EGF, 
0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 50 U/ml penicillin, and 50 µg/ml streptomycin 
at 37°C and 5% CO2. MCF7 cells were maintained in DMEM F12 (1:1). 
 
2.2.2 Western Blot Analysis 
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Lysates were prepared from monolayers of cells in 2x Laemmli sample buffer by boiling 
for 5 min and cleared by centrifugation (Mattingly et al., 2001). Samples were then 
separated on SDS-polyacrylamide gels and electrophoretically transferred to 
nitrocellulose. Membranes were then probed with 1:200 dilutions of anti-RhoA and anti-
pan Ras, 1:500 dilution of anti-Rab5 and 1:600 dilution of anti-unprenylated Rap1 
antibodies, and caspase-3 antibody at 1:1000 dilution (Santa Cruz Biotechnology). LC3-
I and LC3-II were detected using 1:2000 dilution of anti-LC3 antibody (gift from Dr. 
David Kessel, Wayne State University). Cathepsin-B antibody (gift from Dr. Bonnie 
Sloane, Wayne State University) was used at 1:3000 dilution.  
 
2.2.3 Live Cell Imaging Assays 
HEK293 cells were plated into 35-mm culture plates 24 h prior to transfection with 
pRK7.GFP.H-Ras.CaaX using lipofectamine 2000 reagent (Invitrogen) as previously 
described (Norum et al., 2005). Four hours after transfection, fresh media were added 
along with vehicle or drug at appropriate concentrations as stated in the figure legend. 
At the end of treatment, nuclei were stained using a live cell nuclear stain, Hoechst 
33342, followed by confocal live-cell imaging on the LSM-510 at 40x magnification. A 
similar protocol was used to study nuclear morphology of STS-26T cells with or without 
drug treatment. For cellular morphology assays, STS-26T cells and iSC were treated as 
indicated in the figure and differential interference contrast (DIC) images were captured 
on the LSM-510 at 40x magnification. 
 
2.2.4 Immunofluorescence Assays 
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STS-26T cells were plated onto glass coverslips and treated as indicated in the figure 
legends. The cells were fixed and processed for confocal immunofluorecence analysis 
using anti-Lamp-1 or anti-LAMP-2 mouse monoclonal (BD Biosciences), and anti-LC3 
(Abgent, San Diego, CA) rabbit polyclonal antibodies at 1:50 dilution followed by 
appropriate fluorescently-coupled secondary antibodies. The number of LC3-positive 
puncta was quantified using Volocity software 5.2.1 (Perkin Elmer, Waltham, MA). 
 
2.2.5 Cell Proliferation Assay 
STS-26T cells, ST88-14 cells and iSC were plated at ~20,000 cells per 35-mm dish 24 h 
before drug treatment. At appropriate time points, attached cells were trypsinized and 
combined with media containing detached cells. The cells were collected by 
centrifugation for 5 min at 50g and counted via a hemacytometer.  
 
2.2.6 MTT Assay 
Cells were passaged into 96-well plates at a density of 2500 cells per well containing 
200 µl of growth media with inhibitors or vehicle and cultured for 72 h at 37oC. 20 µl of 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Invitrogen, Eugene, 
Oregon) stock solution (5 mg/ml in PBS) was then added and the plates were incubated 
for 4 h. The medium was removed and the formazan precipitate formed was dissolved 
in 150 µl of DMSO. Absorbance values were measured using a plate reader 
(SpectraFluor Plus, Tecan, Salzburg, Australia) at 485 nm wavelength. After 
normalizing the absorbance values for media and vehicle controls, the data were 
analyzed using GraphPad Prism version 4.0c (GraphPad Software Inc., San Diego, CA) 
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by non-linear regression (curve fit) and plotting sigmoidal dose-response to obtain GI50 
values, which were further plotted on an isobologram for synergy analysis (Zhao et al., 
2004).  
 
2.2.7 Flow Cytometric Analysis  
STS-26T cells were treated and collected for DNA analysis as described previously 
(Mattingly et al., 2006). DNA content was analyzed using a FACScalibur instrument (BD 
Biosciences, San Jose, CA). A minimum of 104 cells per sample was analyzed to 
determine the percentage of apoptotic cells and cells in G1, S and G2/M phases (Modfit; 
Variety Software, Topsham, ME). 
 
2.2.8 DEVDase Activity Assay 
Lysates of STS-26T cells were prepared and used for DEVDase assays as described 
previously (Wojtkowiak et al., 2008). Changes in fluorescence over time were converted 
to picomoles of product by comparison with a standard curve made with 7-amino-4-
methylcoumarin. DEVDase specific activities are reported as nanomoles of product 
made per minute per milligram of protein. The bicinchoninic acid assay, using bovine 
serum albumin as a standard, was used to estimate protein concentrations.  
 
2.2.9 Colony Formation Assay 
STS-26T cultures were plated at a density of 2 x 104 per 35-mm culture plate ~24 h 
prior to drug treatment. They were then  treated with either DMSO, 1mM rapamycin or 
with the combination drugs with or without rapamycin for 48 h. At the end of the 
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treatment, cells were collected by trypsinization and centrifugation and 3x103 treated 
cells were sub-cultured in triplicate in 60-mm plates containing fresh media without 
drugs.  Colonies containing 4 or more cells after 48 h and 72 h of growth were counted 
in 10 randomly selected fields per plate. Data were plotted as number of colonies 
against drug treatment. 
 
2.2.10 Lysosomal pH determination using acridine orange (AO) 
STS-26T cells were treated with DMSO, 500 nM lovastatin or 500 nM FTI-1 either alone 
or in combination. At the end of the treatment, media were replaced with media 
containing 200 nM AO followed by incubation at 37oC for 15 min with the addition of 
Hoechst 33342 during the final 5 min. Cells were quickly rinsed with 1X PBS three times 
and immediately imaged using a Carl Zeiss Axiovert 200M fluorescent microscope at 
40x magnification. The filter cubes used for capture of red and green fluorescence 
employed exciter/emitter/beam splitter wavelengths of 365/420/395 nm and 
500/535/515 nm respectively.   
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Figure 2.1: Synthesis of prodrug GGTI-2Z (compound 7), and structures of 2Z-GGMP 
(compound 8) and 2Z-GGPP (compound 9). GGTI-2Z is based on the 7-allyl analog of 
GGPP (compound 2; Maynor et al, 2008). 2-Z-geranylgeraniol (2-Z-GGOH) was 
synthesized from compound 2. It was then converted by phosphoramidation to prodrug 
GGTI-2Z. All synthetic chemistry was performed by the Gibbs laboratory at Purdue 
University. 
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Figure 2.2. Chemical structure of lovastatin. Lovastatin is a naturally occurring 
compound of the statins class of inhibitors of HMG-CoA reductase enzyme.  
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CHAPTER 3 
 
A NOVEL GERANYLGERANYL TRANSFERASE INHIBITOR IN COMBINATION 
WITH LOVASTATIN INHIBITS PROLIFERATION AND INDUCES AUTOPHAGY IN 
STS-26T MPNST CELLS 
 
3.1 RATIONALE 
 
In the past our group has tested prenylation inhibitors including FTIs and statins as 
potential therapies for Type I neurofibromatosis (NF1) (Wojtkowiak et al., 2008) and 
other hyperproliferative disorders (Mattingly et al., 2002). For example, a novel FTI 
compound, FTI-1, in combination with lovastatin induces apoptosis in two different NF1 
MPNST cell lines (Wojtkowiak et al., 2008). Moreover, we observed little to no 
detectable toxicity of the treatment in normal iSC, indicating the potential use of this 
combination treatment for NF1 MPNSTs. The FTase substrate(s) that are affected by 
FTI treatment to produce inhibition of cell proliferation and survival are still unclear. 
However, an interesting study involving a chemical genetics approach revealed 
RabGGTase or GGTase II as a target of FTIs (Lackner et al., 2005). This finding 
supported the idea that FTIs have many different targets that may be responsible for 
their activity and side effects, and also identified a potential role for Rab proteins and 
RabGGTase in p53-independent apoptosis induced by FTIs. It also emphasized the 
potential of GGTIs as an alternative to FTIs. More recently, GGTase I inhibition was 
shown to reduce tumor formation and improve survival in mice with K-Ras induced lung 
cancer (Sjogren et al., 2007). 
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One of our aims in developing prenylation inhibitors is to identify their target substrates 
and their mechanisms of action in the subject cells. Recently, autophagy was suggested 
to be one of the mechanisms by which FTIs may exert their effects on tumor cells (Pan 
et al., 2008). Autophagy is generally thought of as a pro-survival mechanism for cells 
(Glick et al.). The molecular machinery involved in the autophagic process was initially 
identified and characterized in yeast. Most of the autophagy genes are conserved in 
mammals and are regulated similarly (Rubinsztein et al., 2007). There are three known 
types of autophagy: microautophagy, macroautophagy and chaperone-mediated 
autophagy (Scarlatti et al., 2009). Microautophagy involves direct invagination of 
cytoplasm in the form of vesicles at the lysosomal membrane. Chaperone-mediated 
autophagy involves chaperone-assisted translocation of cytosolic proteins containing a 
particular peptide motif across the lysosomal membrane. Macroautophagy, which is 
likely to be most relevant to this study, is a mechanism that involves formation of 
double-membrane vesicles, called autophagosomes that encase cytosol as well as 
whole organelles and ultimately fuse with lysosomes for degradation and recycling of 
contents (Figure 3.1A). A basal rate of macroautophagy (hereafter referred to as 
autophagy) occurs in most cells in order to eliminate damaged organelles or aggregated 
proteins (Scarlatti et al., 2009) and, as suggested most recently, is a mechanism for 
lipid metabolism (Singh et al., 2009). In conditions of nutrient starvation or other stress, 
the process is upregulated and thus serves as a survival mechanism. Owing to its 
cytoprotective nature, autophagy has been implicated as a mechanism to combat 
proteinopathies, including Huntington’s disease and Alzheimer’s disease (Rubinsztein et 
al., 2007). More recently, however, it was suggested that autophagy might in fact result 
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in cell death. This is termed as autophagic cell death and its underlying mechanism is 
yet unknown (Kroemer et al., 2009). Both the cytoprotective and cytotoxic effects of 
autophagy are now being exploited for potential antitumor activity (Turcotte and 
Giaccia).  
 
3.2 RESULTS 
 
3.2.1 Inhibition of geranylgeranylation of GTPases by GGTI-2Z and lovastatin 
combination  
In collaboration with the Gibbs laboratory, previous students from our laboratory have 
recently demonstrated that the monophosphate derivatives of certain FPP analogs are 
potent FTIs, and that prodrugs derived from these analogs block protein farnesylation 
(Clark et al., 2007; Wojtkowiak et al., 2008). The Gibbs laboratory has also synthesized 
and evaluated novel GGPP analogs, and found several analogs that are in vitro 
inhibitors of GGTase I (Gibbs et al., 1999; Maynor et al., 2008; Zahn et al., 2001).  In 
particular, the 2Z GGPP analog, compound 9, from which the prodrug GGTI-2Z was 
synthesized, is an excellent inhibitor of geranylgeranylation of dansyl-GCVLL peptide by 
GGTase I (Zahn et al., 2001), and that the corresponding monophosphate compound 8 
is the most potent GGPP based GGTI yet reported (IC50 = 21 nM).  
In this dissertation, I sought to undertake the first cellular evaluation of GGTI-2Z to 
confirm whether the compound also inhibits geranylgeranylation in vivo. We first tested 
whether this novel GGTI could inhibit geranylgeranylation of Rap1A via GGTase I. STS-
26T cells were treated with 3 µM GGTI-2Z either alone or in combination with 500 nM 
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lovastatin. DMSO treatment was used as a vehicle control. We performed western 
blotting with an antibody that only recognizes the unprenylated form of Rap1A. GGTI-2Z 
alone was unable to inhibit Rap1A geranylgeranylation even after 48 hours of treatment. 
A distinct band representing unprenylated Rap1A appeared within 24 h in whole cell 
lysates treated with lovastatin alone and this unprenylated Rap1A was strikingly 
increased upon treatment with a combination of GGTI-2Z and lovastatin (Figure 3.2A; 
upper panel). The amount of unprenylated Rap1A in comparison to the total Rap1 levels 
(Fig. 3.2A; lower panel) increased over time with the combination treatment. This result 
indicates that GGTI-2Z, when combined with lovastatin, inhibits Rap1A 
geranylgeranylation.  
Another geranylgeranylated protein that has been inhibited in the past by laboratories 
using other GGTI compounds is RhoA. Sebti and colleagues have shown that GGTI 
treatment of pancreatic cancer cells results in an increase in RhoA expression levels 
(Delarue et al., 2007). In our study with GGTI-2Z and lovastatin combination, we saw a 
similar marked increase in the expression level of RhoA within 24 h compared to vehicle 
control, and this increase was maintained even at 48 h of treatment (Figure 3.2B, lanes 
4 and 8).  
We also tested for inhibition of RabGGTase or GGTase II by looking for reduced 
prenylation of Rab5. Strikingly, we observed a clear up-shift due to appearance of 
unprenylated Rab5 upon combination treatment (Figure 3.2C, lane 4) as opposed to 
vehicle or single compound treatments. Additionally, we observed a dose-dependent 
increase in inhibition of Rab5 prenylation. As little as 1 µM GGTI-2Z synergized with 500 
nM lovastatin to effectively inhibit Rab5 prenylation (Figure 3.2D; lane 8). When used 
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singly, at least 1 µM lovastatin was required to observe an inhibition to a similar extent 
(Figure 3.2D; lane 4).. Conversely, as much as 10 µM GGTI-2Z alone failed to have any 
effect on Rab5 prenylation (Figure 3.2D; lane 7). 
In addition to the above proteins, GGTI-2Z and lovastatin were also found to inhibit 
prenylation of Ras and Rab6. There was a distinct band of unprenylated Ras with 
combination treatment, which could include all three isoforms of Ras: H-Ras, N-Ras and 
K-Ras, although our previous analysis of these cells suggests that H-Ras is not 
expressed (Mattingly et al., 2006). When probed for Rab6, there appeared to be a band 
shift, which may imply that Rab6 prenylation was reduced (Figure 3.2E). 
 
3.2.2 Combination of GGTI-2Z and lovastatin does not inhibit FTase 
Prenylation of Ras proteins helps target them to the plasma membrane where their site 
of action lies. These membrane proteins can be fluorescently tagged to visualize their 
cellular localization patterns in the presence or absence of prenylation inhibitors 
(Maurer-Stroh et al., 2007). We transfected HEK293 cells with a construct that encodes 
GFP fused to the CaaX motif of H-Ras (an exclusively farnesylated protein) and then 
treated the cells with our compounds alone or in combination. The nuclei were then 
stained followed by live-cell imaging via confocal microscopy for localization of GFP. As 
seen in Figure 3.3, we observed that in the case of vehicle-treated cells, GFP.H-
Ras.CaaX localizes to the plasma membrane along with some intracellular expression 
that may represent the Golgi (Choy et al., 1999). Treatment with a low dose 
combination of lovastatin and a FTI that we have previously shown to block 
farnesylation (Wojtkowiak et al., 2008), inhibits the membrane localization and induces 
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a diffuse cytosolic distribution of GFP.H-Ras.CaaX. In contrast, as high as 6 µM GGTI-
2Z plus 500 nM lovastatin combination failed to prevent membrane localization of the 
GFP.H-Ras.CaaX protein. These data indicate that GGTase inhibition by GGTI-2Z and 
lovastatin does not inhibit prenylation of the exclusively farnesylated GFP.H-Ras.CaaX 
protein (Figure 3.3).  
 
3.2.3 GGTI-2Z in combination with lovastatin inhibits proliferation of STS-26T 
cells without significant loss of cell viability 
 Next we sought to test the effect of inhibition of geranylgeranylation by the two 
compounds on growth and proliferation of STS-26T cells. We treated the cells with the 
compounds alone or in combination and found that 1 µM concentration of GGTI-2Z or 
lovastatin alone had little effect on proliferation (Figure 3.4A). However, 45 h of 
exposure of the cells to a combination of 3 µM GGTI-2Z and 1 µM lovastatin caused a 
significant inhibition of proliferation of the cells, and this inhibition was similar to the 
extent of 10 mM GGTI-2Z treatment alone (Figure 3.4B). In addition, we characterized 
dose-dependent as well as time-dependent inhibition of proliferation of these cells by 
the combination treatment (Figure 3.4A, 3.4B). In addition to proliferation, we examined 
the percent viability of the cells. At all the time points tested, there was little effect on 
cell viability with single or combination treatments (Figure 3.4D). The inhibition of 
proliferation and lack of significant effect on cell viability was also confirmed via a live 
cell morphology assay (Figure 3.4C). We further tested whether there was synergy 
between the two compounds when used in combination, via an MTT assay.  After 72 h 
of treatment, the data analysis showed that these compounds were indeed synergistic 
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in their growth inhibitory effect (Figure 3.4E).  The synergistic inhibition was indicated by 
the GI50 (concentration of drug required for 50% inhibition of cell growth) values for the 
combination treatment lying below the theoretical line connecting the GI50 values for 
GGTI-2Z and lovastatin alone.  
 
3.2.4 GGTI-2Z in combination with lovastatin arrests STS-26T MPNST cells in 
G0/G1 phase of the cell cycle 
We observed significant inhibition of proliferation of STS-26T cells by co-treatment with 
GGTI-2Z and lovastatin. We therefore next determined which point of the cell cycle 
these compounds targeted in order to inhibit proliferation. We performed flow cytometry 
analysis of STS-26T cells treated with GGTI-2Z and lovastatin singly or in combination 
(Figure 3.5). Our results showed that treatment with 3 µM GGTI-2Z or 1 µM lovastatin 
alone did not affect cell cycle progression. Interestingly, the same concentrations of the 
drugs, when used in combination, induced an accumulation of cells in the G0/G1 cell 
cycle phaseand a simultaneous reduction in percentage of cells in G2/M and S phases. 
These data are consistent with a G1 cell cycle arrest. 
 
3.2.5 GGTI-2Z alone or in combination with lovastatin does not induce apoptosis 
in STS-26T cells 
Although analyses of cell viability by trypan blue exclusion assay suggested no 
cytotoxicity by combined GGTI-2Z and lovastatin treatment, we wanted to re-examine if 
the treatment induced any apoptosis in the cells. For this purpose, we used N-acetyl-
Asp-Glu-Val-Asp-amino-4-methylcoumarin to assay the activity of caspases-3 and -7 
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(Wojtkowiak et al., 2008). HA14-1, a known inducer of apoptosis through inhibition of 
Bcl-2, was used as a positive control for this assay. When treated with HA14-1 for 2 h, 
STS-26T cells showed significant induction of apoptosis as demonstrated by a strong 
increase in DEVDase activation compared to untreated control cells (Figure 3.6A). 
There was even stronger induction of caspase-like activity after 4 h of treatment with 
HA14-1. In contrast, treatment with the prenylation inhibitors alone or in combination did 
not yield any detectable DEVDase activation (Figure 3.6A). As an additional test for 
caspase activation in these cells, we probed lysates of cells treated with the drugs alone 
or in combination, for expression of cleaved caspase-3. As shown in Figure 3.6B, 
procaspase-3, which is the uncleaved form of caspase-3, was evident in all the cell 
lysates at 35 kDa. However, in contrast to HA14-1, the prenylation inhibitors did not 
induce any cleaved caspase-3, indicating lack of detectable apoptosis in these cells by 
this measure. Finally, we also performed nuclear morphology assays using Hoechst 
33342 dye to monitor chromatin condensation as an indicator of apoptosis. Within 45 
min of HA14-1 treatment, we observed nuclear condensation in the form of bright blue 
spots as seen in Figure 3.6C. Conversely, with GGTI and/or lovastatin treatment, 
neither did we see any nuclear morphological changes (Figure 3.6C), nor did we see 
any appearance of DNA laddering (data not shown), which further confirms lack of 
apoptosis in the cells.  
 
3.2.6 GGTI-2Z and lovastatin combination treatment induces autophagy in STS-
26T cells 
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We further investigated whether autophagy was involved in determining the response of 
the cells following prenylation inhibition. This was achieved by assaying LC3, the 
classical marker of autophagy (Klionsky et al., 2008). During the formation of 
autophagosomes, LC3-I is processed to LC3-II via phophatidylethanolamine (PE) 
attachment. Presence of LC3-II is, therefore, associated with occurrence of autophagy.  
We observed a subtle increase with single treatments and a marked increase with 
combination treatment in the appearance of LC3-II in STS-26T cells within 24 h when 
compared with vehicle treatment (Figure 3.7A). This increase was sustained at 48 h. 
This result suggests that the drugs may be inducing or up-regulating the autophagic 
process in these cells.  
Increase in LC3-II levels may be associated with either of two possible mechanisms: an 
increase in formation of autophagosomes or a decrease in processing/degradation of 
LC3-II due to an absence of autophagosome/lysosome fusion or depression of 
lysosomal protease activities (Figure 3.1B).  In order to distinguish between effects on 
synthesis and on degradation, we pretreated the cells with protease inhibitors, E64D 
and pepstatin A. These compounds inhibit lysosomal proteases, which would prevent 
degradation of LC3-II in the autophagolysosome.  The results showed that the protease 
inhibitors did induce a further increase in LC3-II levels (Figure 3.7B), which is consistent 
with there being autophagosome and lysosome fusion, and subsequent proteolytic 
processing in the autophagolysosome.  We also used bafilomycin A1, which blocks the 
maturation of autophagosomes by its inhibition of the vacuolar ATPase.  In this case, 
we treated the cells with the vehicle, single compounds, or combination treatment for 48 
h, with bafilomycin A1 also present for the final 2 h of the incubation.  The results show 
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that the single treatments do not have much effect on autophagic flux compared to 
vehicle control, whereas the combination treatment again increases LC3-II 
accumulation either in the presence or absence of bafilomycin A1 (Figure 3.7C). 
Furthermore, immunocytochemical staining of LC3 along with the lysosomal marker, 
LAMP-2, was also performed following treatments with the compounds as indicated 
(Figure 3.7D). Vehicle or single compound treatments did not result in co-localization of 
the two proteins. In contrast, a very distinct punctate co-localization of LC3 and LAMP-2 
was observed in cells following the combination treatment. Quantitative analysis of LC3-
positive puncta, using two independent LC3 antibodies, revealed an approximately five-
fold increase in the number of punctate structures upon combination treatment as 
compared to DMSO treatment (Figure 3.7E). These results indicate that the autophagic 
process is both induced and proceeds to completion in STS-26T cells co-treated with 
GGTI-2Z and lovastatin. 
 
3.2.7 Inhibitors of autophagy do not affect GGTI-2Z/lovastatin induced autophagy 
in STS-26T cells 
To determine whether GGTI-2Z/lovastatin induce autophagy via the canonical pathway 
involving PI3K and beclin (Figure 3.8C), we used PI3K inhibitors, 3-MA and wortmannin, 
to test their ability to block the induction of autophagy. Upon pre-treatment with these 
inhibitors, there was no blockade of autophagy. In contrast, LC3-II processing was 
enhanced, suggesting an upregulation of autophagy (Figure 3.8A and 3.8B). 
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3.2.8 Withdrawal of treatment of STS-26T cells with GGTI-2Z/lovastatin restores 
their colony forming ability 
Since there was no loss of cell viability upon combination treatment, we investigated 
whether the colony forming ability of the cells was restored upon withdrawal of the drugs 
and replating in fresh media. Rapamycin, a known autophagy inducer, was used as a 
positive control for this assay. We observed that similar to DMSO and rapamycin 
treatment, cells treated with GGTI-2Z/lovastatin, upon withdrawal of the inhibitors and 
replating in fresh media, were able to rescue growth and form colonies (Figure 3.9).  
 
3.2.9 GGTI-2Z and lovastatin combination is also effective in other unrelated 
cancer cell lines 
In order to test the effects of the drugs in cell lines that model other cancers, we 
performed cell proliferation and viability assays in a murine hepatoma cell line, 1c1c7. 
We found that GGTI-2Z and lovastatin combination also inhibits proliferation of these 
cells without significantly affecting their viability (Figure 3.10A and 3.10B). This cell line 
stably expresses a GFP fusion construct of LC3. Upon combination treatment, there 
was increased appearance of LC3-positive vesicles, indicating induction of autophagy 
(Figure 3.10C).  
We also treated cultures of MCF10.DCIS cells with the drugs and assayed for LC3-II 
accumulation by western blotting. The results showed increased LC3 processing 
following dual treatment, confirming autophagic induction in these cells as well (Figure 
3.10D). The above results confirmed autophagy induction by two independent 
techniques in two separate cancer cell lines. 
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3.2.10 GGTI-2Z/lovastatin do not induce autophagy in other MPNST cell lines 
It was an interesting question whether GGTI-2Z/lovastatin exert similar effect of 
autophagy induction on other related MPNST cell lines. To test this, we checked 
proliferation of ST88-14 cells under the influence of the inhibitors and found that similar 
to STS-26T cells, their proliferation is also inhibited significantly by combination 
treatment (Figure 3.11A). Furthermore, we tested the effect on LC3 processing to 
assess autophagy. In contrast to STS-26T cells, however, ST88-14 as well as NF90-8 
cell lines did not exhibit LC3 processing characteristic of autophagic induction upon 
combination treatment (Figure 3.11B).  
 
3.2.11 Normal immortalized rat Schwann cells (iSC) are resistant to GGTI-2Z and 
lovastatin co-treatment 
An effective anti-tumor agent is expected to be highly selective for tumor cells without 
affecting normal cells, such that it is minimally toxic. We, therefore, tested whether 
GGTI-2Z and lovastatin in combination affected proliferation of normal iSC as a 
measure of therapeutic safety. As shown in Figure 3.12A, the compounds either alone 
or in combination had little to no effect on the proliferation of iSC. In addition, we found 
no detectable morphological changes in these cells upon treatment with the compounds 
(Figure 3.12B).   
 
3.3 DISCUSSION 
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In this study, we have developed a novel GGTI whose action is potentiated by co-
treatment with lovastatin, resulting in inhibition of proliferation and cell cycle arrest 
associated with induction of autophagy in STS-26T MPNST cell line. The strategy for 
development of the GGPP-based inhibitor compound, GGTI-2Z, is analogous to that 
previously described for the development of FTIs (Maynor et al., 2008). Of all the GGPP 
analogs evaluated in prior studies, 2Z geranylgeranyl monophosphate compound 8 
served as the most efficacious inhibitor with an impressive IC50 value of approximately 
21 nM for GGTase I enzyme in vitro (Maynor et al., 2008). Encouragingly, this analog 
also exhibited no significant binding to mammalian FTase in vitro, further confirming its 
promise as a tool to evaluate cellular GGTase I inhibition. Additionally, in the first 
cellular evaluation of this compound in this study, as seen by immunocytochemistry, 
GGTI-2Z did not affect the membrane localization of a GFP construct that is exclusively 
farnesylated, suggesting that it acts to solely inhibit geranylgeranylation while 
farnesylation remains unaffected. Furthermore, the fact that it did not have any effect on 
either morphology or proliferation of normal iSC implies lower risk of toxicity to normal 
cells.  
Our rationale for the combinatorial approach was to achieve more efficient GGTase I 
inhibition via GGTI-2Z by simultaneously depleting endogenous GGPP pools. Rap1A is 
a Ras family GTPase that is known to be solely geranylgeranylated presumably by 
GGTase I (Casey et al., 1991). We observed inhibition of Rap1A prenylation, thus 
confirming the previous in vitro result that GGTI-2Z effectively inhibits GGTase I, 
although it does so only when combined with lovastatin. Conversely, lovastatin alone is 
sufficient to modestly inhibit Rap1A geranylgeranylation. These data suggest that 
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Rap1A may not be a critical target for the inhibition of STS-26T cell proliferation, as 
even higher levels of lovastatin (up to 1 µM) do not affect cell cycle distribution. We also 
observed an inhibition of Ras prenylation, however, the cells express detectable levels 
of both N- and K-Ras, warranting further investigation of the isoform(s) involved.  
The combination of GGTI-2Z/lovastatin synergistically inhibits proliferation of STS-26T 
cells. This anti-proliferative activity is consistent with induction of cell cycle arrest in the 
G1 phase. Other GGTIs have also been shown to block cell cycle progression of several 
tumor cell lines and subsequently induce apoptosis (Vogt et al., 1997). However, with 
GGTI-2Z/lovastatin, there was little effect on cell viability and we did not observe the 
classical apoptotic morphology or apoptotic markers in STS-26T cells.   
Another potential determinant of cell survival is the phenomenon of autophagy. In recent 
years, autophagy has been discovered to be an important mechanism adopted by many 
different cell lines for determining their fate, and it is still a topic of debate whether 
autophagy is a cell survival or a cell death mechanism (Apel et al., 2009). Interestingly, 
there is increasing evidence suggesting that several cancer cells show up-regulation of 
the process leading to cell survival and cancer progression (Rubinsztein et al., 2007). 
Recently, three FTIs were found to induce autophagy in two different human cancer cell 
lines (Pan et al., 2008).  In addition, some statins can induce autophagy in a cell-type 
specific manner owing to their ability to inhibit protein prenylation rather than cholesterol 
synthesis (Araki and Motojima, 2008). For instance, cerivastatin or simvastatin are 
capable of inducing autophagy in rhabdomyosarcoma cells (Araki and Motojima, 2008), 
whereas lovastatin or simvastatin fail to do so in hepatocytes (Samari and Seglen, 
1998). We examined our GGTI/lovastatin combination treated cultures to see if 
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autophagy occurred. We also performed autophagic flux experiments using pre-
treatment with protease inhibitors, E64D and pepstatin A, or with bafilomycin A1 
treatment. Based on the analysis of LC3-I conversion to LC3-II via western blot, and the 
co-localization of LC3 with the lysosomal protein LAMP-2 via immunocytochemistry, we 
confirmed that autophagy was induced and driven to completion in STS-26T cultures 
co-treated with GGTI-2Z and lovastatin. The lack of inhibition of autophagy by the 
common PI3K inhibitor, 3-MA, suggests that the autophagic response seen in STS-26T 
cells may be restricted to the non-canonical pathway of autophagy. There is not much 
known about this alternative route of autophagy despite the thought that it may share 
some of its key players with the canonical pathway (Scarlatti et al., 2008b). Albeit, 
analysis of the key initiator of canonical autophagy, beclin1, which is not involved in the 
non-canonical pathway, may assist in dissecting this hypothesis.  
One of our observations shows that the compounds cause dose- and time-dependent 
inhibition of prenylation of Rab5, a GGTase II or RabGGTase substrate. Moreover, 
another Rab protein, Rab6, undergoes a prenylation shift. These data indicate that the 
compounds not only inhibit GGTase I, but also serve as substrates for GGTase II. This 
was not surprising since the two enzymes share strikingly similar active sites (Lackner 
et al., 2005) and hence, a compound designed to bind the GGPP binding pocket of 
either of the two can be expected to bind similarly to the other. The preference of 
binding in that case will be determined by relative affinity of the compound for the 
enzymes. We have not yet tested the in vitro ability of GGTI-2Z to bind to GGTase II to 
determine the KM value. An alternative explanation for the dual inhibition of GGTase I 
and RabGGTase-mediated prenylation is that GGTI-2Z inhibits GGPP synthase, 
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blocking the production of the GGPP substrate needed for both processes (Wiemer et 
al., 2007).  In addition, there is a noticeable decrease in the expression level of Rab5 
upon GGTI-2Z/lovastatin treatment. Potentially, this RabGGTase inhibition and/or 
enhanced Rab5 turnover may contribute to the effects of the compounds on MPNSTs. 
Rab proteins have been shown to play an important role in carcinogenesis (Cheng et 
al., 2004). Originally, Rab5 was known to have a well-established role in endocytosis 
and vesicular transport of proteins (Bucci et al., 1992). More recently, however, an 
interesting study in cell culture and fly models of Huntington’s disease suggested a role 
for Rab5 in the early stages of the process of macroautophagy that is independent of its 
endocytic function (Ravikumar et al., 2008). This study showed that Rab5 inhibition via 
expression of dominant-negative Rab5 results in a decrease in LC3-positive autophagic 
vacuoles, and also enhances polyglutamine toxicity. In the case of our study we saw 
that inhibition of Rab5 prenylation via GGTase inhibition is correlated with an increase in 
LC3-II levels. Prenylation inhibitors may be capable of only partially blocking Rab5 
activity, and thus, the partially prenylated and active Rab5 may still be sufficient for 
autophagic progression. Additional evidence that may support such a connection is that 
fluvastatin and pravastatin-induced RabGGTase inhibition causes vacuolation in rat 
skeletal myofibers (Sakamoto et al., 2007). Alternatively, the GGTI may target one or 
more other protein(s) that may potentially contribute to its action. Further studies would 
be required to better elucidate the role of Rab5 and other proteins in GGTI/lovastatin 
induced autophagy in MPNSTs.  
In conclusion, we have developed a novel compound GGTI-2Z that blocks prenylation 
mediated by both GGTase I and GGTase II, and exerts cytostatic activities in STS-26T 
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MPNST cells in a caspase-3-independent manner. The action of GGTI-2Z is potentiated 
by low-dose statin combination treatment and strongly correlates with induction of 
autophagy. This combination treatment does not block proliferation of, or induce toxicity 
in normal, immortalized Schwann cells, but does have inhibitory activity against two 
other transformed cell lines: 1c1c7 murine hepatoma cells and MCF10.DCIS cells that 
model human breast ductal carcinoma in situ. Further studies toward preclinical 
development of GGTI-2Z may serve to develop better understanding of 
geranylgeranylation inhibitors and to evaluate their potential in the context of cancer 
therapy as well as some Rab-associated protein-trafficking disorders. 
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Figure 3.1: A. The process of autophagy. Initiation of autophagy begins with the 
formation of small sections of membranes called phagophores/phagosomes. These 
phagophores undergo elongation to formed double membrane vesicles called 
autophagophores/autophagosomes. During this process, a protein named as LC3 
undergoes cleavage and modification via phosphatidylethanolamine (PE) attachment to 
form LC3-II, which is localized on the inner membrane of the autophagosomes.  The 
autophagosomes eventually fuse with lysosomes to form autophagolysosomes, where 
the contents including LC3-II are degraded and recycled. Autophagy genes, such as 
Atg7 and Atg3 play distinct roles at several steps throughout this entire process.  
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Figure 3.1: B. Autophagic flux. Induction of autophagy coincides with LC3-II 
processing. However, increase in LC3-II may occur due to two different reasons. One is 
via induction of autophagy. Two is when the last step involving fusion of 
autophagosomes and lysosomes is blocked, leading to reduced degradation and 
increased accumulation of LC3-II in autophagosomes.  
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Figure 3.2: Inhibition of prenylation via GGTase I in STS-26T cells by GGTI-
2Z/lovastatin combination treatment. STS-26T cultures were treated as indicated for 24 
h or 48 h. Whole-cell lysates were probed for prenylation status of Ras superfamily 
GTPases via Western analysis. A. Detection of Rap1A via an antibody directed toward 
the unprenylated form of Rap1A (middle panel), and detection of total Rap1 (lower 
panel). B. Detection of RhoA, which has been reported to be over-expressed following 
block of GGTase (Falsetti et al., 2007).  
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Figure 3.2 contd: Inhibition of prenylation via GGTase II in STS-26T cells by GGTI-
2Z/lovastatin combination treatment. STS-26T cultures were treated as indicated. 
Whole-cell lysates were probed for prenylation status of Rab5 via Western analysis. C. 
Detection of Rab5. Unprenylated GTPases migrate more slowly on SDS-PAGE gels. β-
tubulin was used as a loading control in all western blots. D. Dose-response of Rab5 
prenylation status. Data shown are representative of at least three independent 
experiments. 
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Figure 3.2 contd: Inhibition of geranylgeranylation of additional proteins by GGTI-
2Z/lovastatin. E. Whole cell lysates of treated STS-26T cells were probed for pan-Ras 
and Rab6.  
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Figure 3.3: Lack of effect of GGTI-2Z/lovastatin treatment on membrane localization of 
a farnesylated GFP construct. HEK293 cells were transiently transfected with 
pRK7.GFP.H-Ras.CaaX plasmid, followed by treatment with prenylation inhibitors as 
shown for 16 h. FTI-1/lovastatin treatment inhibited H-Ras.CaaX localization at the 
plasma membrane, whereas GGTI-2Z/lovastatin treatment did not affect the localization 
even at 6 µM GGTI-2Z concentration. Results are representative of three independent 
experiments. 
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Figure 3.4: Effect on proliferation and viability of STS-26T cells following GGTI-
2Z/lovastatin treatment. A and B. STS-26T cells were subjected to treatment as shown. 
Samples were collected at the time of treatment and every 24 h post-treatment for 
analysis of cell number. Data represent means + S.D. of three independent 
experiments. C. Cells were treated as indicated above. After 72 h of treatment, live cell 
differential interference contrast (DIC) images were taken on a LSM-510 at 40x 
magnification. Data are representative of three independent experiments.  
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Figure 3.4 contd.: D. Number of non-viable cells was analyzed with respect to total 
number of cells to calculate percent viability at the given time points. E. Cells were 
treated with the compounds at several different concentrations as shown, alone or in 
combination and the data were tested for synergy using isobologram analysis. Data 
represent means + S.D. of two independent experiments.  
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Figure 3.5: FACS analysis: GGTI-2Z/lovastatin treatment arrests STS-26T cells in 
G0/G1 and increases sub-G1 DNA content. STS-26T cells were treated as shown. 
Cultures were harvested 48 h post-treatment for DNA content by staining with propidium 
iodide. Histograms represent 104 events, and the cell cycle profile was determined 
using MODFIT. Results are representative of two independent experiments. 
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Figure 3.6: Lack of apoptosis in STS-26T cells following GGTI-2Z/lovastatin treatment. 
HA14-1 treated cells were used as a positive control. A. STS-26T cells were treated as 
indicated in the figure. Data represent means of triplicate samples and are 
representative of two independent experiments. B. STS-26T cells were treated as 
indicated in the figure. Attached as well as detached cells were pooled, and whole-cell 
lysates were separated and probed for cleaved caspase-3.  
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Figure 3.6 contd: C. STS-26T cells were treated for 48 h with the indicated 
concentrations of lovastatin and/or GGTI-2Z or for 30 min with HA14-1. Nuclei were 
stained using Hoechst 33342 and live-cell imaging was performed on an LSM510 
confocal microscope at 40x magnification. Data are representative of results from two 
independent experiments. 
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Figure 3.7: Induction of autophagy in STS-26T cells by GGTI-2Z/lovastatin treatment. 
A. STS-26T cells were treated with indicated concentrations of GGTI-2Z and lovastatin 
alone or in combination. B. Cells were subjected to 2 h pretreatment with protease 
inhibitors, 10 µM pepstatin A and 10 µM E64D, followed by the prenylation inhibitors for 
48 h as indicated. C. Cells were subjected to 48 h drug treatment, with addition of 50 
nM bafilomycin A1 for the last 2 h of the incubation. At the end of all treatments, whole 
cell lysates were then probed for LC3 and β-tubulin. Results are representative of three 
independent experiments. 
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Figure 3.7 contd: D. STS-26T cells were treated as indicated for 48 h followed by 
methanol fixation. Cells were then stained for LC3 and LAMP-2. Nuclei were stained 
using DAPI and cells were visualized under the LSM-510 at 40x magnification. E. 
Quantitative analysis of LC3-positive puncta treated with either DMSO or the drug 
combination for 48 h. Data are representative of at least two independent experiments.  
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Figure 3.8: Lack of inhibition of GGTI-2Z/lovastatin induced LC3 processing by known 
autophagy inhibitor, 3-methyladenine (3-MA) (Seglen and Gordon, 1982). STS-26T cells 
were pretreated with 3-MA for 2 h followed by addition of the prenylation inhibitors as 
shown for 48 h. Whole cell lysates were then probed for LC3 and β-tubulin. Data are 
representative of at least two independent experiments. 
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Figure 3.9: Effect on re-plating ability of STS-26T cells upon treatment with GGTI-
2Z/lovastatin followed by removal of the drugs. STS-26T cells were treated as depicted 
on the X-axis for 48 h. At the end of treatment 3x103 treated cells were re-plated in fresh 
growth medium without inhibitors. Colonies containing 4 or more cells from 10 randomly 
selected fields were counted at 48 and 72 h. Data represent mean + S.D. of three 
independent experiments each counted in triplicates. 
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Figure 3.10: Effects of GGTI-2Z/lovastatin on other human cancer cell lines. A, B. 
Cultures of murine hepatoma 1c1c7 cells were treated one day after plating with varied 
concentrations of either lovastatin and/or GGTI-2Z. Cultures were harvested 48 h after 
treatment for assessment of total cell number (A) and viability (B), as assessed by 
ability to exclude trypan blue. Data represent means ± SD of analyses of three culture 
dishes per treatment. Dashed line in panel A represents cell number at time of 
treatment.  
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Figure 3.10 contd: C. Cultures of murine hepatoma 1c1c7 cells that stably expressed 
GFP-LC3 were treated as indicated above for 48 h prior to being analyzed for the 
formation of punctate GFP-LC3 spots (i.e. autophagosomes) by fluorescence 
microscopy. Co-treatment with lovastatin and GGTI-2Z resulted in marked accumulation 
of autophagosomes. D. Cultures of MCF10.DCIS (ductal carcinoma in situ) were treated 
as indicated and lysates were subjected to immunoblotting for LC3. 
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Figure 3.11. Effect of GGTI-2Z/lovastatin on other MPNST cell lines. A. ST88-14 cells 
were treated as indicated. Samples were collected at time points shown and total cell 
number was analyzed using a trypan blue exclusion assay. All treatments were unable 
to affect proliferation of iSC. Data represent mean + S.D. of three independent 
experiments. 
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Figure 3.11 contd: B. Effect of GGTI-2Z/lovastatin on LC3 processing in NF1 MPNST 
cell lines, ST88-14 and NF90-8. Cells were treated as indicated with the prenylation 
inhibitors for 48 h with or without a 2 h pre-treatment with protease inhibitors, 10µM 
E64D and 10µM pepstatin A, and whole cell lysates were probed for LC3 and β-tubulin. 
Data represent results from at least two independent experiments. 
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Figure 3.12: Lack of cytotoxicity from GGTI-2Z/lovastatin in normal immortalized rat 
Schwann cells. A. iSC were treated as indicated. Samples were collected at times 
shown, and total cell number was analyzed. All treatments were unable to affect 
proliferation of iSC. Data represent mean + S.D. of three independent experiments. B. 
iSC were treated as shown in the figure and observed every 24h post-treatment. The 
figure represents the 72 h time point and shows a lack of observable toxicity. 
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CHAPTER 4 
 
INDUCTION OF AN ABORTED AUTOPHAGIC PROGRAM BY COTREATMENT 
WITH A NOVEL FARNESYL TRANSFERASE INHIBITOR AND LOVASTATIN LEADS 
TO NON-APOPTOTIC DEATH IN STS-26T MPNST CELLS 
 
4.1 RATIONALE 
 
In parallel to testing GGTI-2Z, our group has also characterized a related prodrug 
FTase inhibitor called FTI-1 (Figure 4.1) in combination with lovastatin for its antitumor 
effects on MPNST cell lines. Our laboratory has previously published that FTI-1 and 
lovastatin co-treatment induces apoptosis in two different NF1 MPNST cell lines, NF90-
8 and ST88-14 (Wojtkowiak et al., 2008). Interestingly, when tested in the non-NF1 
MPNST cells, STS-26T, the compounds failed to induce apoptosis. We found that there 
was significant inhibition of proliferation that ultimately resulted in cell death; however, 
the typical apoptosis markers were absent. There was no induction of caspase-3/7 
activity or caspase-3 cleavage products.  
Some initial work by a previous student in the laboratory included testing this inhibitor 
combination in the STS-26T cell line and investigating whether the cells may be 
undergoing autophagic cell death (type II cell death). There was indeed a massive 
upregulation of LC3 processing, more so than that with GGTI-2Z/lovastatin co-
treatment. These results suggested that FTI-1/lovastatin also caused induction of 
autophagy. Further autophagic flux measurements using pre-treatment with protease 
inhibitors, however, indicated that this autophagic process does not undergo 
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completion. This aborted autophagy may be a consequence of a blockade of 
autophagosome-lysosome fusion or impaired lysosomal proteolysis. I sought to 
determine which of these possibilities was more likely to occur and the underlying 
mechanism by which the inhibitors may affect lysosomal function.  
 
4.2 RESULTS 
 
4.2.1 FTI-1 plus lovastatin treatment is cytotoxic to and induces aborted 
autophagy in STS-26T cells 
We have previously found that sub-micromolar concentrations of FTI-1 and lovastatin in 
combination disrupt Ras, Rab5 and Rheb prenylation in STS-26T cells (Wojtkowiak, 
J.W.; Thesis, 2009). Measurement of viable cell numbers via a trypan blue exclusion 
assay revealed that this treatment also inhibits proliferation significantly compared to 
vehicle or single treatments (Figure 4.2A). This inhibition occurred with a significant, 
although delayed, loss of cell viability (Figure 4.2B). There was no indication of 
occurrence of apoptosis (not shown), whereas the compounds were found to induce 
autophagy. As mentioned above, autophagic flux experiments with protease inhibitors 
suggested an aborted autophagic phenomenon (not shown). Subsequent flux 
measurement with bafilomycin A1 co-treatment was performed. All the inhibitor 
treatments induced an increase in LC3-II levels when compared with DMSO control. 
Starvation of the cells in leucine-free media and GGTI-2Z/lovastatin, which are known to 
induce autophagy in this cell line were used as positive measures of autophagic flux. 
Bafilomycin A1 was able to induce further increase in LC3-II levels in case of both these 
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treatments. In contrast, there was no further increase in LC3-II expression upon FTI-
1/lovastatin and bafilomycin A1 treatment. (Figure 4.3). This result confirmed aborted 
autophagy in the cells.  
The autophagic pathway is regulated by a protein called mTOR (mammalian target of 
rapamycin (Sarbassov et al., 2005). mTOR is a negative regulator of induction of 
autophagy. Rapamycin is an agent that inhibits mTOR and thus is known to induce the 
autophagic pathway. Treatment of STS-26T cells with this agent depicted a dose- and 
time-dependent inhibition of proliferation similar to that with FTI-1/lovastatin treatment 
(not shown). This inhibition was accompanied by autophagic induction as expected, 
however, autophagic flux indicated completion of autophagy in contrast to FTI-
1/lovastatin treatment (not shown). Colony formation assays were performed to 
measure the re-plating ability of cells treated with FTI-1/lovastatin versus rapamycin 
(Figure 4.4). The re-plating ability of cells was inhibited by FTI-1/lovastatin treatment 
whereas it remained unperturbed by rapamycin treatment. Furthermore, rapamycin was 
unable to protect the cells from FTI-1/lovastatin induced cytotoxicity. These results 
showed that rapamycin had a cytostatic effect whereas FTI-1/lovastatin exhibited a 
cytotoxic effect on STS-26T cells despite the fact that both treatments induced 
autophagy in the cells.  
 
4.2.2 Vesicle fusion events and lysosomal proteins are perturbed by FTI-
1/lovastatin co-treatment 
The aborted autophagy may be a consequence of the effects of the inhibitors on 
autophagosome-lysosome fusion. To investigate this possibility, we performed co-
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immunofluorescence assays by probing for LC3 and LAMP-1 (late endosomal marker) 
or LAMP-2. As seen in the image overlays, single cell magnified images and co-
localization profiles, cells treated with DMSO, single drugs or leucine-free media 
showed substantial co-localization of LC3 with both LAMP-1 and LAMP-2 (Figures 4.5, 
4.6). On the other hand, the extent of co-localization was reduced in cells co-treated 
with FTI-1 and lovastatin. These results suggest that the vesicle fusion events may be 
inhibited, leading to LC3-II accumulation.  
Surprisingly, as suggested by decreased intensity of fluorescence detection of LAMP-2 
(Figure 4.6) western blotting indicated markedly reduced level of LAMP-2 in the co-
treated cells. While there was no effect on LAMP-1 expression upon treatment, the 
combination treatment resulted in dramatic attenuation of LAMP-2 coupled with the 
appearance of a higher mobility form of the protein, which may depict a LAMP-2 
degradation product (Figure 4.7). LAMP-2 depletion has previously been reported in a 
rat model of acute pancreatitis as a consequence of lack of autophagosome-lysosome 
fusion (Fortunato and Kroemer, 2009) as well as in transformed cells with high cysteine 
cathepsin levels and activity (Fehrenbacher et al., 2008).  
Loss of LAMP-2 expression as well as lack of fusion could be a consequence of 
lysosomal disruption or loss of lysosomal acidity. Lysosomal pH was inspected using 
acridine orange (AO) dye, which fluoresces orange-red when present in the acidic 
environment of intact lysosomes (Moriyama et al., 1982). AO staining indicated that at 
the early 24 h time point, distinct lysosomal structures appeared as depicted by orange-
red staining under all treatment conditions (data not shown). However, at 36 h there 
was some diffuse staining indicating lysosomal dispersion and a further conspicuous 
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dispersion at 48 h with combination treatment as opposed to other treatments. Thus, 
although lysosomes were present and acidic, they were mislocalized (Figure 4.8).     
 
 
4.2.3 Procathepsin trafficking defects and subsequent impairment of cathepsin 
activity following prenylation inhibitor treatment 
Next, we investigated the latter possibility of proteolysis impairment by the drugs. This 
mechanism was explored by evaluating the expression and activity of lysosomal 
cathepsin proteases that are known to contribute to the degradation of 
autophagolysosome contents, including cathepsins B and D. These cathepsins are 
cysteine proteases that are post-translationally modified in the ER and Golgi followed by 
trafficking through the endocytic pathway (Victor and Sloane, 2007). Protein expression 
analysis and activity assays indicated lack of mature, active proteases and concurrent 
accumulation of their consecutive inactive pro-forms. In cultures treated with DMSO, 
500 nM lovastatin or 500 nM FTI-1, three forms of cathepsin B (pro-form; mature single 
chain form; and the heavy chain of mature, double-chain cathepsin B), and the pro-form 
and the heavy chain of mature, double-chain cathepsin D appeared. Co-treatment with 
FTI-1/lovastatin led to dramatic accumulations of procathepsins B and D, along with 
loss of the mature cathepsins (Figure 4.9). One possibility for loss of mature cathepsins 
was their secretion into the extracellular media. Nevertheless, western blot analysis did 
not show any detectable mature cathepsin B in concentrated extracellular media (not 
shown), refuting this idea. Moreover, when assayed for cathepsin B activity via a 
substrate-based activity assay as well as by using an activity-based probe, there was 
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substantially less activity in combination treated cells compared to vehicle control (data 
not shown). These observations confirm that FTI-1/lovastatin co-treatment of STS-26T 
cells led to impaired procathepsin trafficking.  
 
4.2.4 MCF7 cells exhibit aborted autophagic program and lysosomal dysfunction 
upon co-treatment 
One important question in this study was whether this aborted autophagic phenomenon 
occurs in any other tumor cell line, particularly considering that the other MPNST cell 
lines tested failed to undergo apoptosis upon treatment with the inhibitors. MCF7 breast 
cancer cells were treated with the compounds and lysates were analyzed for LC3 
expression. We observed that similar to STS-26T cells, MCF7 cells showed an 
induction of autophagy as depicted by an increase in LC3-II expression levels (Figure 
4.10A). Additionally, there was no further increase in LC3-II level upon bafilomycin A1 
co-treatment, confirming that these cells also undergo aborted autophagy upon FTI-
1/lovastatin treatment. This result was further substantiated by appearance of potential 
LAMP-2 degradation products via western blot analyses (Figure 4.10B).  
 
4.3 DISCUSSION 
 
FTIs have previously been shown to act on tumors via several different mechanisms 
including cell cycle inhibition, proteasome inhibition, apoptosis and so on (Efuet and 
Keyomarsi, 2006; Tamanoi et al., 2001; Wojtkowiak et al., 2008). A recent advancement 
in this field was when Pan et al showed that FTIs are capable of inducing autophagy in 
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tumor cells (Pan et al., 2008). Statins were also found to induce autophagy in some 
tumor cell types (Araki and Motojima, 2008). In fact, before these studies were 
published, statins were indirectly implied to induce autophagy-like phenotype (then 
termed as vacuolation) in rat skeletal myofibers followed by apoptotic cell death 
(Sakamoto et al., 2007). However, the mechanism of autophagic induction and its 
consequences by these inhibitors remained a mystery. In the MPNST cell line tested in 
this study, STS-26T, we observe a similar phenomenon of autophagy induction, but 
there was a distinct difference in the drug-induced phenotype in the form of aborted 
autophagy and non-apoptotic cell death. This type of cell death (also termed autophagic 
cell death) has also been observed in some other studies, particularly in apoptosis-
resistant cell lines. For instance, rapamycin was reported to induce autophagic cell 
death in malignant glioma cell lines, U87-MG and T98G (Takeuchi et al., 2005). There 
has been a missing link and an unexplained association of autophagy and autophagic 
cell death in this and other such reports. In our study, the investigation of the underlying 
mechanism of this phenomenon in STS-26T cells has led us to reveal important 
mechanistic aspects of ‘autophagic cell death’ observed in our case and perhaps many 
other cases. It also raises an important issue as to whether autophagic cell death 
occurs as a consequence of aborted autophagy versus the previous assumption of 
excessive autophagy.  
The autophagic pathway often involves Rheb/mTOR signaling cascades. The mTOR 
complex 1 (mTORC1) activity when suppressed, induces autophagy (Meijer and 
Codogno, 2009). In addition, farnesylation of Rheb, a small GTPase that stimulates 
mTORC1, has been shown to be necessary for autophagy signaling (Buerger et al., 
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2006; Castro et al., 2003). These studies support our idea that Rheb may serve as a 
critical target of the inhibitors. On the other hand rapamycin, which inhibits mTOR, did 
induce autophagy but was not cytotoxic. Based on this result, the involvement of mTOR 
signaling in aborting autophagy and interfering with endocytic trafficking may be 
discounted, but it may still be valid to consider it as a player in the induction of the 
autophagic process.  
The lack of colocalization of LC3 with LAMP-1 and LAMP-2 clearly depicted a fusion 
defect in co-treated cells. Switching cells to leucine-free media, which is known to 
induce autophagy and drive autophagosome-lysosome fusion, showed distinct punctate 
vesicular structures positive for both proteins being detected, presumably 
autophagolysosomes. Apparently similar structures were diminished in cotreated 
cultures. Further confirmation of this defect was the dramatic loss of LAMP-2 expression 
in these cultures. Although LAMP-1 and LAMP-2 are both heavily glycosylated 
transmembrane proteins associated with lysosomes, the deficiency of LAMP-2 in mice 
exhibits a more severe phenotype than LAMP-1 deficiency (Tanaka et al., 2000). 
Therefore, despite sharing common functions with LAMP-1, LAMP-2 has been 
suggested to play a more critical role in lysosomal function (Eskelinen et al., 2002). It is 
thought to act as a selective receptor on lysosomal membranes for import and 
degradation of cytosolic proteins inside the organelle (Cuervo and Dice, 1996, 1998). 
Furthermore LAMP-2, but not LAMP-1, is required for proper fusion of autophagosomes 
and lysosomes (Gonzalez-Polo et al., 2005). An interesting observation is that the 
phenotype seen in our double treatment exposed cells is very similar to that seen in the 
cells of patients suffering from a lysosomal storage disorder, called Danon disease. 
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Danon disease is caused by a primary deficiency of LAMP-2 protein due to mutations or 
aberrant splicing of the LAMP-2 gene (Di Blasi et al., 2008; Nishino, 2006). The most 
striking pathological feature associated with this deficiency is the accumulation of 
autophagosomes in myofibers (Saftig et al., 2008). Based on this knowledge, we 
believe that LAMP-2 may be a critical player in the effects of FTI-1/lovastatin on STS-
26T cells.  
An investigation of whether the lysosomal fusion defects arose from disruption of 
lysosomes or from other lysosomal defects such as lack of acidity clarified that 
lysosomal occurrence and their pH remained unaffected even at later time points after 
treatment when loss of cell viability had already occured. This result showed that intact 
lysosomes were still present after co-treatment and their pH rendered acidic. These 
studies were very important since they eluded to an alternate mechanism of lysosomal 
dysfunction in the cells.  
Since there was no obvious physical defect in the lysosomes upon treatment, we 
questioned the integrity of the lysosomal enzymes. Lysosomes are composed of several 
cathepsin proteinases that digest lysosomal contents. Most cathepsins are synthesized 
in the ER and then trafficked inside vesicles to the lysosomes via the trans-Golgi 
network via mannose-6-phosphate (M6P) receptors (Victor and Sloane, 2007). 
Cathepsins B and D are lysosomal cysteine proteases that are commonly found in the 
lysosomes. Cathepsin D deficiency as well as double deficiency of cathepsins B and L 
have been associated with a lysosomal storage disorder called lipofuscinosis in murine 
CNS neuronal and Drosophila models (Koike et al., 2000; Koike et al., 2005; Kuronen et 
al., 2009). Additionally, the neuronal model also exhibited autophagosome accumulation 
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in the cells. In our study, the lack of procathepsin processing and cathepsin activity in 
FTI-1/lovastatin treated cells confirmed impairment of trafficking of active cathepsins to 
lysosomes. This result explains why lysosomes, although intact, do not function and 
cause the autophagosome fusion defect. The loss of LAMP-2 may also be partly due to 
its trafficking impairment, albeit the LAMP-2 trafficking mechanism is thought to be 
separate from the cathepsin trafficking mechanism (Hasilik et al., 2009; Karlsson and 
Carlsson, 1998). One interesting theory behind the impaired lysosomal enzyme 
trafficking that could be worth investigating is the loss of function or number of M6P 
receptors.  
To summarize, our findings indicate that although STS-26T cells are capable of 
undergoing apoptosis like with HA14-1 treatment, prenylation inhibition by FTI-
1/lovastatin fails to do so and rather stimulates the autophagic route. MCF7 cells, which 
lack caspase-3, are apoptosis-incompetent and thus exhibit similar consequences of co-
treatment. Hence we conclude that autophagy is a predominantly active pathway in 
STS-26T cells and that the cells are highly dependent on autophagy. Drug-induced 
interference with this pathway coupled with cell cycle arrest leads to cell death.  
Overall, we believe that the aborted autophagic program induced by FTI-1/lovastatin in 
STS-26T cells is a consequence of a procathepsin trafficking defect, which coupled with 
LAMP-2 deficiency, renders the lysosomes dysfunctional. The resulting accumulation of 
autophagosomes impairs protein turnover and ultimately causes cell death.  
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Figure 4.1: Chemical structure of FTI-1. The synthesis of prodrug FTI-1, which was 
earlier reported as compound 5c, has been previously described in Clark et al, 2007. 
FTI-1 was synthesized by our collaborator, Dr. Richard Gibbs’ group. Upon entry inside 
the cell, the prodrug moiety is cleaved while releasing the FPP analog, which can act as 
a competitive inhibitor of FPP. 
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Figure 4.2: Effect of FTI-1/lovastatin on proliferation and viability of STS-26T cells. 
STS-26T cells were plated 24 h prior to being treated with DMSO, lovastatin, FTI-1, or a 
combination of FTI-1 plus lovastatin. Cultures were harvested at various times after 
treatment as shown for estimates of cell numbers (A) and viability (B) by Trypan blue 
exclusion assays.  
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Figure 4.3: Autophagic flux experiment. STS-26T cells were subjected to 4 h in leucine 
free media, or 48 h of DMSO, or 500 nM GGTI-2Z or 500 nM FTI-1 either alone or in 
combination with 500 nM lovastatin as indicated, without or with addition of 50 nM 
bafilomycin A1 for the final 2 h of the culture. Whole-cell lysates were then separated on 
SDS-PAGE gels and analyzed for LC3 and β-tubulin expression. 
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Figure 4.4: Colony formation assay. STS-26T cultures were treated as described in the 
figure for 48 h. At the end of the treatment, 3x103 treated cells were replated in fresh 
growth medium without inhibitors. Colonies containing 4 or more cells from 10 randomly 
selected fields were counted at 48 and 72 h post-replating. Rapamycin treated cells 
formed colonies following 48 h of treatment. Data represent mean + S.D. of 3 
independent experiments counted in triplicates. 
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Figure 4.5: Colocalization of LC3 and LAMP-1 in FTI-1 and lovastatin co-treated 
cultures. STS-26T cultures were treated with DMSO, 500 nM lovastatin, 500 nM FTI-1 
or FTI-1 plus lovastatin for 48 h prior to processing of cultures to analyze colocalization 
of LC3 with LAMP-1. Nuclei were stained with DAPI. Parallel cultures were shifted to a 
leucine-free media for 6 h in order to intentionally induce autophagy. Co-localization of 
LC3 with LAMP-1 is indicated by punctate orange/yellow fluorescence in overlaid 
images, or congruence of overlaid scans of the red and green channels. Magnified 
images show the cells that were analyzed to generate colocalization profiles. 
Colocalization profiles were generated by analysis of a random line drawn through a 
single cell per field and plotting fluorescence intensity against distance along the line in 
microns. 
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Figure 4.6:  Colocalization of LC3 and LAMP-2 in FTI-1 and lovastatin co-treated 
cultures. STS-26T cultures were treated with DMSO, 500 nM lovastatin, 500 nM FTI-1 
or FTI-1 plus lovastatin for 48 h prior to processing of cultures to analyze colocalization 
of LC3 with LAMP-2. Nuclei were stained with DAPI. Parallel cultures were shifted to a 
leucine-free media for 6 h in order to intentionally induce autophagy. Co-localization of 
LC3 with LAMP-2 is indicated by punctate orange/yellow fluorescence in overlaid 
images, or congruence of overlaid scans of the red and green channels. Magnified 
images show the cells that were analyzed to generate colocalization profiles. 
Colocalization profiles were generated by analysis of a random line drawn through a 
single cell per field and plotting fluorescence intensity against distance along the line in 
microns.
  96 
 
 
 
Figure 4.7: Effects of FTI-1 and lovastatin co-treatment on LAMP-1 and -2 expression. 
STS-26T cultures were treated with lovastatin, FTI-1 or lovastatin plus FTI-1 for either 
24 or 48 h prior to being processed for quantification of LAMP-1 and LAMP-2 
expression by western blot analysis. Parallel cultures were shifted to a leucine-free 
media for 6 h in order to intentionally induce autophagy. Analyses are of 25 µg of 
protein per lane.  
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Figure 4.8: Effect of FTI-1/lovastatin treatment on lysosomal acidity. STS-26T cells 
were treated with DMSO, lovastatin or GGTI-2Z either alone or in combination for 36 
and 48 h as indicated. At the end of the treatment, media were replaced followed by AO 
treatment at 200 nM concentration for 2 min. Cells were then quickly rinsed and fresh 
media added followed by imaging by fluorescence microscopy. 
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Figure 4.9: Effects of FTI-1 and lovastatin co-treatment on pro-cathepin B/D 
processing. A. STS-26T cultures were treated with solvent, lovastatin, FTI-1, or 
lovastatin + FTI-1 for 16-62 h prior to the preparation of whole cell lysates and analyses 
of pro-cathepsin B/D processing by western blot analyses. Analyses presented in 
panels A and B utilized 25 µg protein per lane. Blots are representative of data obtained 
in a minimum of 3 independent experiments.  B. STS-26T cultures were treated as 
described in panel B, but processed for measurements of cathepsin B activity. C. STS-
26T cells were treated with DMSO or FTI-1 + lovastatin for 48 h prior to localizing active 
cysteine cathepsins with GB117, a quenched activity based probe.  Size bar, 10 µm. 
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Figure 4.10: Effect of FTI-1/lovastatin on MCF7 breast cancer cells. MCF7 cells were 
treated with DMSO, 500 nM GGTI-2Z or 500 nM FTI-1 either alone or in combination 
with 500 nM lovastatin as indicated for 48 h without or with 50 nM bafilomycin A1 for the 
final 2 h of the culture. Whole-cell lysates were then separated on SDS-PAGE gels and 
analyzed for (A) LC3 and (B) LAMP-2 expression.  β-tubulin was used as a loading 
control. 
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CHAPTER 5 
 
PRENYLATION INHIBITORS AND AUTOPHAGY 
  
5.1 DISCUSSION 
Prenylation inhibitors and their anti-tumor potential have been an interesting topic of 
investigation for years. Despite continual efforts, however, their use in the clinic as anti-
tumor agents has not yet been approved for this purpose. We are still in an urgent need 
of highly effective agents of this class of therapeutics in order to exploit their benefits 
and for their translation from the bench to bedside (Wojtkowiak et al., 2008). Addressing 
the most critical issues that hamper the progress of existing agents would be one 
method to achieve significant success in this area. Our approach of combining novel 
analog-based prenyl transferase inhibitors with lovastatin was an effort in this direction. 
As discussed in Chapter 1, our combinatorial strategy may help scale down the 
physiological doses and alleviate toxic side effects at the same time. This study has 
shown that our novel compounds, GGTI-2Z and FTI-1, may be beneficial in MPNSTs as 
well as many other tumor cell lines broadening their range of application in cancer. 
Future studies in different animal models of cancer will be required to address their 
potential as antitumor therapeutics.  
One of the major questions that we addressed in this study was to identify the 
mechanism(s) of action of the drugs in STS-26T MPNSTs. We found that there was a 
cell cycle arrest in the G1 phase and there was no apoptosis, but an induction of 
autophagy. Both FTI-1 and GGTI-2Z in combination with lovastatin induced autophagy, 
but they regulated the pathway in different ways. This observation was very interesting 
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since there have been a few direct reports of autophagic induction by prenylation 
inhibitors and none of those studies used GGTIs. Additionally, these earlier reports did 
not clarify the exact mechanism(s) of autophagy. Specifically, Pan et al showed that the 
FTI lonafarnib induced autophagy in U2OS osteosarcoma cells and the naturally 
occurring FTI manumycin A showed a similar effect in Panc-1 pancreatic cancer as well 
as U2OS cell lines. These cell lines were in fact undergoing both autophagy and 
apoptosis since lonafarnib-induced autophagy was potentiated by the presence of a 
pan-caspase inhibitor, z-vad.fmk (Pan et al., 2008). In contrast, STS-26T cells solely 
undergo autophagy under the influence of our inhibitors and seem to be highly 
dependent on this pathway. Some statins were also found to induce autophagy in a few 
of the tested cancer cell lines (Araki and Motojima, 2008). In addition, a small molecule 
inhibitor of Icmt induced autophagic cell death in prostate cancer cells (Wang et al., 
2008b). However, the mechanism of autophagic cell death in this case is unclear. In our 
study, we have been able to address many of the questions regarding cell death as a 
consequence of therapy-induced autophagy.  
Based on the results presented, we describe a model (Figure 5.1). In STS-26T cells, 
GGTI-2Z/lovastatin inhibits prenylation of its target substrate proteins, which are yet 
unknown despite some clues. This inhibition leads to a complete autophagic induction 
response in the cells. In the same cell line, FTI-1/lovastatin also inhibits prenylation of 
its unidentified target proteins, which also induces an autophagic response. However, 
this autophagy is aborted owing to a secondary effect wherein autophagosome-
lysosome fusion is prevented by the treatment, coupled with impairment of procathepsin 
trafficking to lysosomes and LAMP-2 degradation (Figure 5.1). There still remain a few 
  102 
unanswered queries in this model. Some of those are listed below and ways to address 
them have also been discussed. 
Autophagy is often initiated by a protein called Beclin 1, which forms a multiprotein 
complex with hVps34 (human vacuolar protein sorting 34) or phosphatidylinositol-3-
kinase (PI3K), to initiate the formation of preautophagosomal structures [reviewed in 
(Scarlatti et al., 2009)]. This is the classical or canonical autophagy pathway. In 
contrast, non-canonical autophagy is thought of as a process that does not require the 
entire set of autophagy-related (Atg) proteins in particular Beclin 1, to form the 
autophagosome. This was shown by the lack of effect on non-canonical autophagy by 
the knockdown of Beclin 1 or of its binding partner hVps34 (Scarlatti et al., 2008b). In 
addition, it is suggested that PI3K inhibitors such as 3-MA do not inhibit non-canonical 
autophagy (Scarlatti et al., 2008a). The lack of inhibition of FTI-1/lovastatin or GGTI-
2Z/lovastatin induced autophagy by 3-MA implies that the co-treated STS-26T cells may 
be undergoing non-canonical autophagy. This idea needs further scrutiny by 
determination of effect of inhibitor treatment on beclin-1 expression, since upregulation 
of beclin-1 is essential for induction of PI3K-induced autophagy (Wang et al., 2008a). 
On the other hand, both canonical and non-canonical forms of autophagy occur with 
mTOR inhibition (Scarlatti et al., 2009). To further identify the role of mTOR complex in 
the observed autophagy, the downstream phosphorylation substrates of mTOR, namely 
S6kinase and 4EBP1, can also be evaluated. Reduced phosphorylation of these 
kinases would imply mTOR inhibition and involvement of mTOR signaling in therapy-
induced autophagy. Additionally, the compounds also inhibit another player that is part 
of the mTOR complex 1, thus emphasizing the role of this complex in autophagy 
  103 
induction. 
Two different prenylation inhibitor compounds (FTI-1 and GGTI-2Z) in combination with 
lovastatin have part similar and part varied effects on STS-26T cells. GGTI-2Z/lovastatin 
induces a complete autophagic response in the cells accompanied by growth arrest, 
whereas FTI-1/lovastatin induces an aborted autophagic pathway followed by cell 
death. The cause(s) for observing similar initial responses but different endpoints in the 
same cell line are yet to be determined. There are multiple hypotheses that could 
explain this discrepancy. One, the difference could be attributed to separate cellular 
targets of the two compounds. Two, the autophagic pathway may be influenced by the 
two compounds at different points, driving the pathway in distinct directions. Three, 
autophagy may not be a direct response to prenylation inhibition and an unknown 
mechanism may be the missing link driving the cellular response to these inhibitors. 
A thorough consideration of each of these possibilities may not necessarily be feasible. 
For instance, in case of the first one, there are hundreds of potential target proteins in 
the cell for both compounds. The modifying enzymes being common for a host of these 
target proteins, the compounds presumably modify prenylation of multiple proteins at 
any point of time in any given cellular system. Additionally, alternative prenylation 
occurs more commonly than thought. Although there may be clues indicating the 
involvement of certain specific proteins, it is more than likely that more than one of 
these is critical for the compounds to exhibit their effects. For this reason, it may be 
challenging to assertively identify the target proteins. Nonetheless, our observations do 
point towards some GTPases that may potentially be evaluated for their involvement. 
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5.1.1 Ras and Rheb as potential targets of prenylation inhibitors 
STS-26T cells express predominantly N-Ras and some K-Ras (Mattingly et al., 2006). 
Both of these isoforms can be farnesylated or geranylgeranylated. Although there was 
inhibition of Ras prenylation with cotreatment, it is not clear which isoform(s) were 
affected. Moreover, the different isoforms may signal via distinct membranes including 
the ER, Golgi, endosomal and plasma membranes (Silvius, 2002). Kaul et al have 
shown that activated H-Ras and K-Ras are capable of stimulating type II cell death 
(non-apoptotic cell death) in glioblastoma cells, and Ras farnesylation and membrane 
association are integral events in this process. They also indicate that modified and 
activated Ras may signal via a unique effector pathway to induce autophagy (referred to 
as vacuolation) (Kaul et al., 2007). If this holds true in STS-26T cells, Ras may not be a 
critical target of the prenylation inhibitors for inducing autophagy. Nevertheless, 
downregulating specific isoforms of Ras to check if there is an effect on the autophagic 
response may reveal the importance of Ras as a target for the compounds.   
Rheb is a small GTPase that is exclusively farnesylated and interacts with mTORC1 
(Bai et al., 2007). A previous study suggested that Rheb is a potential target of the FTI 
lonafarnib (Basso et al., 2005). Our study partially agrees with this idea since FTI-
1/lovastatin was found to substantially inhibit Rheb farnesylation at a time point prior to 
autophagic induction. On the other hand, GGTI-2Z/lovastatin also induces autophagy 
but may not inhibit Rheb farnesylation. Again, silencing Rheb expression prior to 
inhibitor treatment and evaluating effects on autophagic induction may help solve this 
mystery.  
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5.1.2 Role of Rabs in prenylation inhibitor induced autophagy 
Rab proteins were originally thought to be solely involved in endocytosis and vesicular 
trafficking (Bucci et al., 1992). More recently, some Rabs have been found to be key 
regulators of autophagic events. For instance, Rab5 is required for the initiation of 
autophagosome formation (Ravikumar et al., 2008). Also, Rab7 is not only implicated in 
transport from early to late endosomes, but also is a key factor in lysosome biogenesis 
(Bucci et al., 2000). Rab7 mutation leads to an accumulation of procathepsin D and 
cation-independent M6P receptors in early endosomes (Press et al., 1998). We have 
shown in the present study that the compounds inhibit Rab5 prenylation. Thus, we 
suggest that Rab5 and possibly Rab7 or other Rab proteins involved in vesicular 
trafficking may be important targets. Silencing Rab5 or Rab7 may interfere with either 
the induction or fusion steps in the autophagic pathway.  
 
The second hypothesis to explain why the two compounds exert different effects on 
STS-26T cells is already strengthened by the fact that FTI-1/lovastatin induces the 
autophagic pathway as well as inhibits autophagosome-lysosome fusion, whereas 
GGTI-2Z/lovastatin does not show the latter effect. One method to evaluate this 
hypothesis is to protect the lysosomes from FTI-1/lovastatin induced insult and 
determine whether autophagy is no longer aborted.  
 
5.1.3 Lysosomal protection and autophagy 
FTase is a zinc metalloenzyme and its activity in vitro is potentiated by Mg2+. Hence, 
FTase inhibition may lead to zinc imbalance affecting oxidation status of the cells. There 
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is evidence that accumulation of zinc potentiates oxidant-induced lysosomal membrane 
permeabilization and autophagy in astrocytes and cultured hippocampal neurons 
(Hwang et al., 2008; Lee et al., 2009). This may be the cause of the lysosomal toxicity 
we observed upon FTI-1/lovastatin treatment. Therefore, if the free zinc released by 
treatment is chelated using a cell-permeable zinc chelator such as 1,10-phenanthroline, 
it may partly rescue the lysosomes and prevent the aborted autophagy. Consequently, 
there may be a complete autophagic response similar to that with GGTI-2Z/lovastatin. 
One of the issues with this idea is that it is not clear whether FTI treatment destabilizes 
FTase and causes zinc to be released. Furthermore, it is also not known if there would 
be a substantial alteration of zinc levels to lead to a significant downstream effect. If 
future kinetic studies reveal answers to these queries, it may be worthwhile to 
investigate our hypothesis.  
 
Finally, it is not yet clear whether autophagy is a direct consequence of prenylation 
inhibition in these cells, which leads to investigation of the third possible mechanism. 
One feasible way to work toward this aim is to inhibit the induction of autophagy and 
observe the effects on protein prenylation as well as on the fate of STS-26T cells. 
 
5.1.4 Modulation of Atg genes  
The Atg (autophagy) gene family consists of several genes involved in the autophagic 
process. These genes play different roles in the induction and implementation of the 
autophagic pathway in the cell. Atg5 forms a complex with Atg12 in a reaction that 
requires Atg7 and Atg10. Atg5-Atg12 conjugates form the pre-autophagosomal 
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structures (PAS), initiate the elongation process and dissociate upon autophagosome 
formation. Thus, Atg5 is required for the very initial steps in the formation of 
autophagosomes. Atg5-knockout (Atg5-/-) mouse embryonic stem (ES) cells were found 
to be deficient in autophagosome formation (Mizushima et al, 2001). Atg5-deficient mice 
are born normally, but die neonatally (Kuma et al, 2004). Hence, preventing autophagic 
induction in STS-26T cells via a knockdown of Atg5 may be a useful tool to evaluate the 
role of autophagy in the effect of prenylation inhibitors on these cells. 
Atg5 knockdown is expected to inhibit the induction of autophagy. Since both FTI-1 and 
GGTI-2Z were found to induce autophagy, the knockdown may prevent this effect. This 
inhibition may compromise the cell’s innate ability to program its survival or death, and 
may lead to upregulation of compensatory pathways including apoptosis and necrosis. 
This is especially likely with GGTI-2Z/lovastatin treatment, which would mean that the 
role of autophagy under the influence of GGTI-2Z/lovastatin is cytoprotective in these 
cells. Most likely, though, there may be a host of other alternative consequences, 
especially considering that along with autophagic induction, FTI-1 treatment in Atg5 
wild-type cells also leads to a mysterious non-apoptotic cell death.  
FTI-1/lovastatin not only induces autophagy but also causes compromised lysosomal 
activity via altered procathepsin trafficking, LAMP-2 deficiency and impaired 
autophagosome-lysosome fusion, and an aborted autophagic program. Atg5 
knockdown in this case will completely abolish the autophagic pathway of cell content 
recycling. This may result in toxic accumulation of cellular contents and massive cell 
death.  
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In case of GGTI-2Z/lovastatin treatment, we may alternatively observe reversion of 
effect. The cells may eventually overcome the cell cycle arrested state after sufficient 
period of time when the drugs are metabolized and no longer effective. The 
ubiquitin/proteasome pathway may compensate for loss of autophagic lysosomal 
degradation.  
 
5.2 CONCLUSION 
In conclusion, we have characterized novel prenylation inhibitors, GGTI-2Z and FTI-1, 
which in combination with lovastatin inhibit proliferation of STS-26T MPNST cells. They 
induce cell cycle arrest in the G1 phase and act synergistically with low dose lovastatin 
without affecting normal immortalized Schwann cells. GGTI-2Z induces autophagy and 
is cytostatic while FTI-1 induces an aborted autophagic phenotype and is cytotoxic. This 
is the first ever study showing antitumor potential of a GGTI compound via the 
mechanism of autophagic induction. This is also a novel study showing autophagic cell 
death as a consequence of an aborted autophagic program. In addition, our findings 
emphasize the importance of autophagy and lysosomal function in the action of 
prenylation inhibitors as antitumor agents. The strategy of combination therapy with 
prenyl transferase inhibitors and statin and their novel mechanisms of action may be 
potentially useful to develop better therapeutic regimen for cancer treatment as well as 
certain Rab-associated protein trafficking disorders.  
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Figure 5.1. Model of autophagy regulation by prenylation inhibition. The compounds 
once intracellular are activated by prodrug cleavage. GGTI-2Z/lovastatin can inhibit 
prenylation of yet unidentified target GTPases, e.g. Rabs, and this serves as a positive 
stimulus for autophagy induction and completion. FTI-1/lovastatin also inhibits 
prenylation of unknown targets and induces autophagy. In addition to this effect, 
however, it also affects the lysosomal function via blockade of procathepsin trafficking to 
lysosomes and LAMP-2 degradation. This lysosomal dysfunction presumably leads to 
accumulation of toxic material in autophagosomes and ultimately cell death. 
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Prenylation pathways have been targeted via several different compounds that inhibit 
farnesyl transferase (FTase) and/or geranylgeranyl transferase (GGTase) enzymes in 
many cellular and animal models of cancer. Some of these have also been evaluated in 
clinical trials with limited success. Multiple mechanisms of action have been elucidated 
for such compounds, including cell cycle arrest, proteasome inhibition, apoptosis and 
most recently, autophagy. However, there is still an urgent need of effective agents of 
this class of anti-tumor therapeutics. In this dissertation, I sought to delve into this issue 
by characterizing our novel prenylation inhibitors and their potential as anti-tumor 
agents. Novel compounds, GGTI-2Z and FTI-1, were used in combination with 
lovastatin in STS-26T malignant peripheral nerve sheath tumor (MPNST) cells. We 
found that GGTI-2Z/lovastatin inhibit proliferation, cause cell cycle arrest in the G1 
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phase and induce autophagy in STS-26T MPNST cells. FTI-1/lovastatin not only inhibit 
proliferation and cause cell cycle arrest, but also induce an aborted autophagic program 
followed by non-apoptotic cell death in STS-26T cells. This distinct phenotype observed 
with FTI-1/lovastatin is the consequence of their action on the lysosomal trafficking of 
proteins. The compounds impaired procathepsin trafficking via the endocytic pathway 
along with degradation of the lysosomal protein, LAMP-2, which is required for 
autophagosome-lysosome fusion. These effects consequently lead to altered protein 
turnover and hence non-apoptotic cell death. Our observations identify a novel 
mechanism of action of GGTIs. We also show that autophagic cell death can be a 
consequence of an aborted autophagic program versus excessive autophagy. This 
mechanism also suggests that prenylated proteins may play an important role in a 
complete autophagic response and blocking their prenylation may interfere with this 
function of these proteins. Finally, the strategy of combination therapy with low doses of 
a statin and an FTI or a GGTI compound may serve as a useful tool to develop better 
therapeutic regimen for many cancers and other Rab-associated trafficking disorders.  
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